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The objective of my project is to identify the candidate TSGs and cancer related 
genes which were silenced by aberrant promoter methylation in tumors. High-
resolution 1-Mb array-CGH results show frequent deletion at 1 Iq24.2-q25 in a panel 
of cell lines of nasopharyngeal carcinoma (NPC) and esophageal carcinoma (ESCC), 
both prevalent in Hong Kong. Loss of heterozygosity of Ilq24.2-q25 has also been 
reported in multiple carcinomas, indicating the presence of critical TSGs. Semi-
quantitative RT-PCR was performed for the 34 candidate genes located in this region 
in a panel of NPC and ESCC cell lines with proper normal tissues as controls. I 
identified six genes with frequent transcription silencing or partial downregulation. 
These genes are ADAMTS8, HNT, BARX2, FLIl, ADAMTS15, and ST14. 
Considering their potential functions as TSGs, the first three genes were further 
studied in detail. Their expression levels were analyzed in multiple cancer cell lines 
including hepatocellular, breast, gastric, colon, cervix and renal carcinomas. And 
frequent downregulation was also found in these tumors. The promoter methylation 
of the three genes was analyzed with methylation-specific PCR (MSP) and bisulfite 
genomic sequencing (BGS). The results revealed that ADAMTS8, HNT, BARX2 
showed promoter methylation in 100%, 83%, 30% of NPC cell lines and 12%, 100%, 
i 
8% of ESCC cell lines respectively. Their aberrant methylation is correlated with 
downregulation. Furthermore, the promoter of ADAMTS8 was methylated in 12% of 
NPC primary tumors examined but not in normal tissues. To elucidate whether these 
genes were silenced by aberrant promoter methylation, the cell lines were treated 
with pharmacologic demethylation agent, 5-aza-2‘-dexoycytidine. The results 
indicated that the aberrant promoter methylation and transcription silencing could be 
reversed by pharmacologic demethylation. Lastly, the full length cDNA of the three 
genes were cloned in the pcDNA3.1 expression vectors and the tumor growth 
inhibition function of ADAMTS8 was evaluated by colony formation assay. The 
results revealed that ectopic expression of ADAMTS8 in tumor cell lines would 
inhibit colony formation significantly. 
In this study, several candidate tumor suppressor genes were identified and 
they are frequently inactivated by aberrant promoter methylation in tumors. These 
findings might lead to better understanding of the molecular basis of NPC and ESCC, 
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Chapter One: General Introduction 
Cancer is a diseases characterized by uncontrolled division of abnormal cells and the 
ability of these cells to invade other normal tissues, either by direct growth into 
adjacent tissue through invasion or by implantation into distant sites by metastasis. 
Three types of changes usually occur during the transit from a normal cell to a cancer 
cell. They are immortalization, transformation and metastasis. Immortalization 
describes the acquisition by the cell of the ability to grow through an indefinite 
number of divisions in culture. Based on immortalization, transformation consists of 
a series of changes that release growth constraints on the immortalized cells. For 
example, the transformed cell has reduced serum-dependence, obtains the anchorage 
independent growth ability as well as losses the density-dependent growth inhibition. 
Furthermore, transformed cell may form tumors when injected into appropriate test 
animals. Metastasis describes the milestone of the ability of flilly tumorigenic, 
indicating that the cell gains the ability to invade normal tissue so that it can move 
away from the tissue of origin and establish new colony elsewhere in the body. 
Cancer may affect people at all ages, but risk tends to increase with age in 
most cancer types. It has been estimated that 40% of cancer cases could be prevented, 
mainly by not using tobacco, having a healthy diet, being physically active and 
preventing infections that may cause cancer. i Metastases are the major cause of death 
of cancers. Therefore, a third of cancers could be cured if detected early and treated 
adequately.^ Although the technologies on cancer screening, early detection and the 
methods for cancer therapy keep on developing in the past decades, cancer persists to 




million people died of cancer worldwide, accounting for 13% of the total deaths� 
The situations in Hong Kong are more serious. According to Hong Kong cancer 
registry data^, the crude incidence rates are 368.1 and 289.2 for male and female 
separately in per 100,000 people in year 2004. The mortality to incidence ratios reach 
0.59 in male and 0.45 in female. Totally, the cancer responsible death accounts for 
around 30% of all deaths. When the prevalence of different cancer types were 
concerned in Hong Kong, cancers in lung, liver, colon, breast, nasopharynx and 
esophagus are the most common forms. 
Nasopharyngeal carcinoma (NPC) is a squamous-cell carcinoma that occurs 
in the epithelial lining of the nasopharynx. The nasopharynx is defined as the portion 
of the pharynx which lies behind the nasal fossae and extends inferiorly as far as the 
level of the soft palate. Esophageal squamous cell carcinoma (ESCC) is malignancy 
origins from the squamous cell epithelium of the esophagus. NPC and ESCC are 
both endemic diseases and prevalent in Southern Asia including Southern China such 
as Hong Kong. Their annual incidence rates reach � 3 0 and ~ 100 per 100,000 people 
for NPC and ESCC respectively in the prevalent regions.(1997) The geography 
diversity suggests that specific environmental factors play important roles in the 
etiology of both of these cancers. Interestingly, an overall male to female incidence 
ratio about 3:1 was reported in both of these cancers.(Yu and Yuan 2002; Pickens 
and Orringer 2003) The mortality rates of both NPC and ESCC remain high because 
most cancer cases were presented at late stages due to lack of any specific symptoms 
at early stages.(Lo et al. 2004; Enzinger and Mayer 2003) 
Until the present time, people's understanding on the cause and process of 
tumorigenesis is still very limited.(Campisi 2000) Cancer is proposed to originally 
1. http://www.iarc.fr/ 
2. http ://www3.ha. org.hk/cancereg/ 
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arise from one single cell transformed due to multiple mutations. These mutations 
confer growth advantages and help the descendent cells to throw off the growth 
constrains and dominate the population. During the progression of cancer, some of 
the cells in the dominant population accumulate more mutations and grow more 
aggressively.(Nowell 1976) Hence, the cancer progression processes from a pre-
cancerous lesion to malignant tumors are driven by multiple cycles of mutation and 
clonal selection. The development of cancers may firstly initiated by inherited 
genetic factors and/or external agents. In this process defects in various cancer genes 
accumulate step by step. Actually every tumor type has revealed an enormous 
complexity of altered gene functions. Generally, these genes with direct effects on 
the initiation and progression of cancer can be divided into two groups, including 
growth-promoting genes (oncogenes) and tumor suppressor genes (TSGs).(Balmain 
2002b) TSGs are a cluster of genes needed for the normal growth of cells, but 
contribute to tumor development when their normal functions are inactivated. The 
wild type products of TSGs are usually related to the control of cell growth and/or 
division which are critical to normal cell function.(Plass 2002) In the past decades, 
the epidemiological studies defined some risk factors and environmental factors 
which might be responsible for the geographic distribution diversity of NPC and 
ESCC. One good example is to confirm the relationship between EBV infection and 
oncogenesis of NPC. The genetic susceptibility was also implicated. However, 
generally speaking, the molecular pathogenesis of NPC and ESCC, especially 
regarding the cancer genes critical for the cancer initiation and progression, is still 
poorly known. 
Unlike oncogenes, which accelerate tumor growth after obtaining aberrant 
activation through gain of function change, TSGs, function in tumorigenesis through 
3 
a recessive loss of function fashion. Almost all of the autosomal human genes 
possess two active alleles. Therefore Knudson proposed the hypothesis that both 
alleles needed to be silenced to fully inactivate the functions of TSGs.(Knudson, Jr. 
1971) Some cytogenetic aberrations (e.g. chromosome deletion, loss of 
heterozigosity (LOH) and intragenic mutation) are responsible for these loss of 
function changes. Hence it is well recognized that the chromosome regions of 
deletion in cancers could be used as markers for the isolations of candidates TSGs. 
High-resolution 1-Mb array-CGH results showed frequent deletion at chromosome 
1 Iq24.2-q25 in a panel of NPC and ESCC cell lines. (Tao et. al., data not published.) 
LOH of 1 Iq24.2-q25 has also been reported in NPC, ESCC and multiple carcinomas 
including breast carcinoma, ovarian cancer and lung cancer etc. These well 
established specific deletions in tumors at chromosome 1 Iq24.2-q25 indicate the 
presence of critical TSGs. 
In addition to genetic abnormalities such as deletion, epigenetic changes are 
also recognized as important alternative mechanisms contributing to the malignant 
phenotype of cancer cells mainly through inactivation of TSGs.(Baylin and Herman 
2000) Epigenetic is defined as a set of reversible and heritable changes of DNA 
which may regulate gene expression but without any changes in DNA sequence. The 
best characterized epigenetic change associated with tumorigenesis is the 
transcriptional silencing due to aberrant DNA methylation, particularly within the 
promoter CpG islands of critical TSGs.(Baylin and Herman 2000) DNA methylation 
in human typically occurs at the cytosine which is immediately followed by a 
guanine in the DNA sequence (so called "CpG sites"). CpG sites are found to mainly 
gather in the typical regions called CpG islands, while most the CpG islands are 
found in the promoter regions of genes (about 40% of the mammalian genes). 
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Interestingly, the methylation statuses of the promoter CpG sites are correlated with 
gene transcription activity. In normal cells, most CpG island sites in gene promoters 
are unmethylated, permitting active gene transcription. However, in cancer cells, 
aberrant promoter methylation has been found in those genes, associated with 
transcriptional silencing of the genes. One or both alleles of some TSGs have been 
demonstrated to be inactivated in this way. One example is the famous putative 
tumor suppressor, pl6, which has been reported to be frequently inactivated as the 
result of promoter methylation in a plenty of tumor types. Therefore, Knudson's two 
hit model hypothesis has been revised and promoter methylation has been recognized 
as another alternative mechanism for TSG inactivation.(Jones and Laird 1999) To 
distinguish with the classical "class I" TSGs, which lose function by genomic 
materials deletion, rearrangement or mutation(Haber and Harlow 1997), the "class 
11" TSGs were specially defined to highlight those TSGs which might be functionally 
inactivated but with structure DNA sequence intact. Aberrant promoter DNA 
methylation has been recognized as the most common pathway for the inactivation of 
these class II TSGs,(Jones and Laird 1999; Baylin and Herman 2000; Balmain 2002a) 
which can also served as markers for the identification of novel class II TSGs. In the 
past decade, a broad spectrum of novel techniques were invented and widely applied 
to analyze the methylation alterations at different levels. Mainly, two broad 
approaches can be distinguished: the total genomic approaches and the sequence 
specific approaches. The total genomic approaches can be used to identify and 
characterize differentially methylated regions of genomic DNA and to isolate 
specific genomic fragments with methylation changes. They give a global picture of 
the total content of methylated cytosines in the given DNA samples but with less 
sensitivity. The commonly used methods include Restriction Landmark Genomic 
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Scanning (RLGS)(Hayashizaki et al. 1993), Methylation-sensitive Representational 
Difference Analysis (MS-RDA)(Kaneda et al. 2003), Methylation-sensitive 
Arbitrarily Primed PCR (AP-PCR)(Liang et al. 2002) and CpG Island 
Microarrays(Yan et al. 2001). Oppositely, the sequence specific approaches provide 
sequence specific data about methylation with high accuracy. The representative 
methods include methylation-specific PCR (MSP)(Herman et al. 1996a) and bisulfite 
genomic sequencing (BGS)(Frommer et al. 1992) and a quantitative analysis method 
called Combined Bisulfite Restriction Analysis (COBRA)(Xiong and Laird 1997). 
Combining the multiple methylation analysis approaches, our group identified 
several novel class II TSGs such as GADD45G(y 'mg et al. 2005), PCDH10{Ymg et 
al. 2006) and DLC7(Seng et al. 2007). 
In this thesis, I tried to identify candidate TSGs at 1 Iq24.2-q25 inactivated by 
aberrant promoter methylation in NPC and ESCC. To achieve this objective, all the 
genes located on chromosome 1 Iq24.2-q25 tumor suppressor loci were retrieved and 
investigated. Through expression profiling using semiquantitative RT-PCR study, the 
genes with specific transcriptional downregulation in a panel of NPC and ESCC cell 
lines compared to proper normal tissue controls were identified. Considering the 
tumor suppressor functions, some of these genes with downregulation were further 
studied. Their expression levels were analyzed in multiple carcinoma cell lines 
including hepatocellular, breast, gastric, colon, cervix and renal carcinomas. The 
promoter methylation was analyzed with MSP and BGS. MSP is a novel PCR based 
method used to analyze the methylation status of some specific CpG sites in DNA. 
The bisulfite-treated DNA was amplified with either a methylation-specific primer 
set or an unmethylation-specific primer set. The different primer sets are specifically 
designed to distinguish the differential sequence conversions between the methylated 
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and unmethylated DNA. The BGS analytical method is an important supplement 
method which could study each CpG sites methylation status in detail in a specific 
fragment of DNA. To elucidate whether these genes were silenced by aberrant 
promoter methylation, the cell lines were treated with pharmacologic demethylation 
agent, 5 -aza-2‘-dexoycytidine, to check whether the aberrant promoter methylation 
and transcription silencing could be reversed. Lastly, the full length cDNA of the 
genes were cloned into the pcDNA3.1 expression vectors and the tumor growth 
inhibition function would be evaluated by colony formation assay. One aspect in 
which cancer cells are distinguished from normal cells is that cancer cells allow 
colony formation whether growing on the monolayer plate or cultured in the depth of 
soft agar. The cell colony is characterized as cluster of cells growing together. This 
indicate that cancer cells lose the cell contact growth inhibition character and grow in 
an anchorage independent way. The colony formation assay is established on this 
principle and is a method to analyze the speed of colony formation. By these 
approaches, the epigenetic alterations of several functional candidate TSGs and 
cancer related genes would be identified. 
Through the research work described above, candidate TSGs with 
methylation mediated silencing will be identified in NPC and ESCC. Their promoter 
methylation may be used as tumor markers to detect early tumors, monitor early 
recurrence and predict prognosis and treatment response. 
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Chapter Two: Literature Review 
2.1 DNA methylation 
2.1.1 Epigenetic changes 
Epigenetic changes are defined as a set of reversible heritable changes which 
regulate gene expression but without any changes in DNA sequence.(Baylin and 
Herman 2000) It is now widely accepted that the human genome information 
contains two sides. One side is the genetic information which includes both the genes 
coding sequence and the non-coding sequence of the DNA. The genetic DNA 
sequence provides the blueprint for the manufacture of all the protein and other 
substance necessary. The other side is the epigenetic information which may provide 
additional instruction on how, where and when the genetic information should be 
used. Epigenetic changes play crucial roles on chromatin structure modulation, 
genomic imprinting and X-chromosome inactivation.(Dunn et al. 2003) Generally, 
epigenetic regulations are composed of three systems: DNA methylation, histone 
modification, and RNA-associated expression silencing, which regulate gene 
expression from different aspects but might interact with each other.(Jones 2005) 
DNA methylation in human typically occurs at the so called "CpG sites". 
That is, methylation specifically occurs on the cytosine that is immediately followed 
by a guanine in the DNA sequence. The methylation involves the covalent addition 
of a methyl group to the C-5 position of the cytosine ring and converts the cytosine 
to 5-methylcytosine.(Fig. 2-l)This reaction is catalyzed by DNA methyltransferases 
(DNMTs) in vivo, using S-adenosyl-methionine as the donor molecule for the methyl 
group (CH(3)).(Bestor and Verdine 1994) To date, three members of the DNMT gene 
family have been identified and they are named DNMTl, DNMTSa and DNMTSb 
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separately. All of them showed highly conserved DNA sequence among eukaryotes, 
suggesting a central role of these proteins for development.(Bestor 2000) DNMTl is 
the most abundant DNA methyltransferase and is considered to be the key DNA 
methylation maintenance methyltrasferase. It shows a higher affinity for 
hemimethylated substrates and is required for the maintenance of DNA methylation 
patterns established by the de novo methyltransferases after DNA 
replication.(Pradhan et al. 1997) However, DNMT3a and DNMT3b are recognized 
as the key enzyme exerting the de novo DNA methylation.(Okano et al. 1999) These 
three members are all required for embryonic development since targeted knock-out 
disruption of these enzymes in mice would cause embryonic lethality.(Okano et al. 
1999) Furthermore, this methylation reaction can be blocked by the drug 5-
azacytidine or its equivalents. When this drug is incorporated into genomic DNA, it 
forms a covalent complex with methyltransferase active sites (it contains a nitrogen 
in place of carbon at the 5 position of the cytidine ring. Fig. 2-1). In this way it acts 
as a direct and irreversible inhibitor of DNMTs, resulting in a loss of DNA 
methylation with each round of cell division.(Juttermann et al. 1994) 
Another kind of epigenetic change, hi stone modification, includes acetylation, 
methylation and phosphorylation of conserved lysine residues located in the histone 
tails. There are increasing evidences indicating that characteristic histone 
modification such as deacetylation and methylation of histone would lead to 
chromatin condensation and blockage of transcription initiation. (Jenuwein and Allis 
2001) Moreover, it has been proposed that histone modifications cooperate with 
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Fig. 2-1. (Adopted from Singal and Ginder，1999) Schematic representation of 
the biochemical pathways for cytosine methylation, demethylation, and 
mutagenesis of cytosine and 5-mC. DNMTs catalyze the methylation reaction of 
the position 5 of the cytosine ring, using S-adenosyl-methionine as the donor 
molecule for the methyl group. This reaction can be blocked by the drug 5-
azacytidine. When this drug is integrated into DNA, it could replaces the natural base 
cytidine and forms a covalent complex with methyltransferase. However, the methyl 
group could not be incorporated since it contains a nitrogen in place of carbon at the 
5 position of the cytidine ring. In this way, a loss of methylation would be generated 
at each round of cell division and the effects of so called demethylation are observed. 
The cytosine and 5-methyl cytosine both have the potential to convert to thymidine 
through the process of deamination. Nonetheless, 5-methyl cytosine is much more 
opt to this transition mutation because a deamination reaction occurred on cytosine 
could be repaired immediately by uracil DNA glycosylase. 
2.1.2 Differential methylation pattern in normal and tumor cells 
Generally, the targets of DNA methylation, CpG dinucleotides, have been observed 
to be present with much lower frequency in the sequence of mammalian genomes 
than would be expected due to random chance. Scarano et al. proposed that the CpG 
deficiency is due to an increased vulnerability of methylcytosines to transition 
mutation in genome with CpG cytosine methylation as shown in Fig. 2-1. (Scarano et 
al. 1967) Furthermore, the remaining CpG dinucleotides are not equally distributed 
in the genome. The CpG dinucleotides are found to be much richer in some 
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repetitive sequences and so-called CpG islands. CpG islands are defined as sequence 
longer than 200 bp with GC content of over 50% and an observed over expected ratio 
of CpG of 0.6 or greater. (Gardiner-Garden and Frommer 1987) Actually, most of 
the CpG islands are found in promoter regions of mammalian genes (about 40% of 
genes), with a subset being located in the exonic or intronic sequences or 3' 
downstream region of genes.(Costello et al. 2000) 
In human genomes, 70-80% CpG sites are methylated including the ones in 
the repetitive sequence. The remaining CpG sites which are protected from 
methylation are found mostly located in the CpG islands correlated with gene 
promoter.(Antequera and Bird 1993) However, fully methylated CpG islands 
harbored in the promoter region of genes are also found but only in the silenced 
genes on the inactivated X-chromosome of females and silenced allele of imprinted 
autosomal genes.(Surani 1998) These observations led to the speculation that 
hypermethylation of CpG sites in the promoter region of a gene may be correlated 
with the expression repression of the gene.(Bird 1993) Although the mechanisms of 
how promoter methylation lead to gene expression repression have not been fully 
elucidated, previous studies have suggested that it might work mainly by interfering 
the binding of transcription factors and disturbing the normal chromatin 
configuration. A typical actively transcribed CpG rich promoter is protected from 
methylation. Around the promoter region, there are widely spaced, non-compacted 
nucleosomes with acetylated histones, allowing full access of transcription activator 
complex including hi stone acetylase (HAT), co-activator (CA) and basal 
transcription factors (TF), while DNMTs are excluded from the region. However, 
when the promoter becomes methylated, more evenly spaced and more compacted 
nucleosomes with deacetylated histones could be observed. The promoter is now 
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fully accessible to DNMTs but block the binding of transcription activator complex 
described above.(Herman and Baylin 2003) 
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Fig. 2-2. (Adopt from Herman and Baylin, 2003) Distribution of CpG 
dinucleotide in the human genome and differences in methylation patterns 
between normal and tumor cells. In human genome, which is depicted here as 
exons 1, 2, and 3 of a sample gene (boxes 1，2, and 3), introns of the gene (line 
between the exons), and regions outside the gene, the CpG dinucleotide has been 
depleted during evolution, as shown by the small number of such sites (circles). 
Small regions of DNA, approximately 0.5 to 4.0 kb in size, harbor the expected 
number of CpG sites and are termed CpG islands. Most of these are associated with 
promoter regions of approximately half of the genes in the genome (numerous circles 
surrounding and within exon 1 of the sample gene). In normal cells (upper panel), 
most CpG sites outside of CpG islands are methylated (black filled circles), whereas 
most CpG-island sites in gene promoters are unmethylated (white open circles). This 
methylated state in the bulk of the genome may help suppress unwanted transcription, 
whereas the unmethylated state of the CpG islands in gene promoters permits active 
gene transcription (arrow in upper panel). In cancer cells (below panel), the DNA 
methylation and chromatin patterns are shifted. Many CpG sites in the bulk of the 
genome and in coding regions of genes, which should be methylated, become 
unmethylated, and a growing list of genes have been identified as having abnormal 
methylation of promoters containing CpG islands, with associated transcriptional 
silencing (the symbol X at the transcription start site). 
Fig. 2-2 demonstrated the reverse methylation patterns in normal cells and 
tumor cells. In normal cells, the CpG islands in the transcription favorable promoters 
are unmethylated, whereas the areas immediately downstream, both within the gene 
body and more 3' region, show the CpG depletion and hypermethylation typical for 
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most of the genome. However, the methylation patterns are dramatically altered in 
the cancer cells. In brief, the promoter CpG islands turn to be heavily methylated 
while their downstream areas show hypomethylation which is also typical in the 
cancer cell genome. The CpG rich repetitive elements, which are usually methylated 
in normal cells, also turn to be hypomethylated in cancer cells. As a consequence, 
there is a global hypomethylation in the tumor genome which could be verified by 
assays determining demethylation in specific sequence. (Feinberg and Vogelstein 
1983) 
2.2 TSGs 
2.2.1 Cancer initiation, progression and cancer genes 
Cancer is a genetic disease of somatic cells caused by accumulation of a series of 
mutations in multiple genes. These mutations offer the selective outgrowth of the 
variant progeny with the most vigorous proliferative and/or survival properties. The 
genes recurrently mutated in cancer can be divided into two classes: protooncogenes 
and TSGs.(Hanahan and Weinberg 2000; Marshall 1991; Plass 2002) 
Oncogenes are firstly defined through the ability to drive the process of 
oncogenesis. They are distinguished from their normal cellular counterparts, the 
protooncogenes, by the fact that they harbor gain-of-function mutations. These 
mutations result in activation of protooncogenes either through an over or aberrant 
expression of the normal gene products or through expression of altered gene 
products. Oncogenes are activated in a dominant fashion since abnormality in one 
allele is very potent. This constitutive activation will contribute to the stimulation of 
cell growth, inhibition of apoptosis, and/or differentiation. The class of 
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protooncogenes contains a wide variety of genes including cytoplasmic messengers 
(e.g. RAS), transcription factors (e.g. MYC), and growth factor genes (e.g. Wnt). 
In contrast to oncogenes, TSGs act recessively and are affected by loss-of-
function mutations. In 1970s, Kundson proposed his famous "two hit" hypothesis to 
indicate that both alleles of a TSG needed to be inactivated for totally lose of the 
gene function. (Fig. 2-3)(Knudson, Jr. 1971) Under normal conditions, the proteins 
encoded by TSGs are essential for the normal cell function, involving in the 
inhibition of cell growth, stimulation of differentiation, and/or active cell death. The 
gene products include regulators of cell cycle (e.g. RB), regulators of signal 
transduction pathways (e.g. APC), and transcription factors (e.g. WT-1). Notably, 
TSGs also includes genes involved in the DNA repair pathway (e.g. hMSH2) due to 
the fact that they are also affected by loss-of-fiinction mutations in cancer. (Plass 
2002) 
It has been suggested that most and perhaps all of the cancer cell genotypes 
are a manifestation of six essential alterations that collectively dictate malignant 
growth. The six alterations are self-sufficiency in growth signals, insensitivity to 
growth-inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis，and tissue invasion and 
metastasis.(Hanahan and Weinberg 2000) Actually, the normal functions of the well 
recognized TSGs cover all of the six aspects. 
2.2.2 TSGs could be inactivated through promoter hypermethylation 
According to Knudson two-hit hypothesis(Knudson 2001)，as shown in Fig. 2-3, 
inactivation of TSG functions need a complete loss of both alleles of the related 
genes. Some cytogenetic aberrations (e.g. chromosome deletion, loss of 
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heterozigosity (LOH) and intragenic mutation) are responsible for this loss of 
function change. As well as genetic changes, epigenetic changes such as 
hypermethylation of gene promoter region including CpG islands are alternative 
mechanism for the inactivation of TSGs. Therefore, cancer is also an epigenetic 
disease.(Jones and Laird 1999) 
A growing number of TSGs or cancer related genes have been identified to be 
silenced specifically in tumor in an epigenetic mechanism including promoter 
hypermethylation. The table below (Table 2-1) lists some of reprehensive genes, the 
tumor type correlated and their proposed roles in tumorigenesis. 
Table 2-1. Genes silenced in cancers in association with promoter 
hypermethylation 
Gene Function Tumor Types Refs 
Tumor suppressor genes mutated in familial cancers 
VHL Angiogenesis inhibitor Clear cell renal (Herman et al. 1994) 
PI6 Cell cycle regulation, involved in Most solid, (Herman et al. 1995) 
senescence lymphoma 
E-cadherin Homotypic epithelial cell-cell Ductal breast, (Graff et al. 1995) 
adhesion thyroid, gastric and 
others 
hMLHl DNA-mismatch repair Colon, gastric and (Herman et al. 1998) 
endometrial 
(MIN+) 
BRCAl DNA-damage repair Breast and ovarian (Esteller et al. 2000b) 
LKBl Serine, threonine kinase Hamartomatous (Esteller et al. 2000a) 
colon, breast 
Other important genes 
APC Cell adhesion, signal transduction, Breast (Esteller et al. 2000c) 
cell cycle and apoptosis 
CDH13 Cell-cell adhesion Colorectal (Toyooka et al. 2002) 
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CDXl Proliferation inhibition; Colorectal (Suh et al. 2002) 
Regulation of differentiation 
DAPKl Kinase mediator of interferon Lung and B-cell (Katzenellenbogen et 
induced apoptosis lymphomas al. 1999) 
ER Receptor for estrogen induced Breast, colon, (Issa et al. 1994) 
transcription activation leukemia and others 
FHIT Regulation of proliferation and Lung, breast (Zochbauer-Muller et 
apoptosis al. 2001) 
GSTPl Prevention of oxidative DNA Breast, prostate and (Lee et al. 1994) 
damage renal 
KLKIO Inhibition of anchorage- Breast (Li et al. 2001) 
independent growth 
MGMT Repair of DNA guanosine methyl Brain, colon, lung (Esteller et al. 1999) 
adducts and lymphoma 
OTUD4 Cell growth inhibition Breast (Krop et al. 2001) 
PI5 Cyclin-dependent kinase inhibitor AML, ALL (Herman et al. 1996b) 
P73 P53-like gene Lymphomas (Corn et al. 1999) 
PRDM2 Transcription regulation Breast, lung (Du et al. 2001) 
PTGS2 Regulation of prostaglandin Colorectal (Toyota et al. 2000) 
synthesis 
PYCARD Induction of apoptosis Breast (Conway et al. 2000) 
RARE Apoptosis, involved in Breast (Widschwendter et al. 
senescence, inhibition of 2000) 
proliferation 
RASSFIA Apoptosis, Inhibition of tumor Lung (Dammann et al. 
growth 2000) 
SFN Cell cycle regulation Breast (Ferguson et al. 2000) 
SOCSl Inhibition of cell growth, HCC (Yoshikawa et al. 
induction of apoptosis and 2001) 
regulation of SRAT activation 
SYK Inhibition of tumor growth and Breast (Yuan et al. 2001) 
metastasis 
THBSl Inhibition of angiogenesis and GBM (Kang et al. 2001) 
invasion 
TIMP3 Inhibitor of tissue Colon, renal and (Bachman et al. 1999) 
metalloproteinase brain 
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Fig. 2-3. (Adopted from Jones and Laird, 1999) Loss of TSG function in cancer 
and Knudson,s two-hit hypothesis revised. Two transcription active alleles 
(indicated by arrows) of a TSG are indicated by the two boxes shown at the top. The 
classical Knudson two-hit model involves an initial mutational event (indicated as 
Mut) followed by another genetic inactivation event such as LOH as shown in the 
panel (a). In the new revised Knudson two hit model as shown in the panel (b, c and 
d), the first step of gene inactivation is shown as a localized mutation on the left or 
by transcriptional repression by DNA methylation (indicated as Me) on the right. The 
second hit is shown by either LOH or transcriptional silencing. In this way, DNA 
methylation functions as an alternative mechanism for the inactivation of TSGs. 
2.3 NPC 
Nasopharyngeal carcinoma is a non-lymphomatous, squamous-cell carcinoma that 
occurs in the epithelial lining of the nasopharynx. The nasopharynx is defined as the 
portion of the pharynx which lies behind the nasal fossae and extends inferiorly as 
far as the level of the soft palate. The fossa of Rosenmiiller represents the most 
common site of origin of NPC. This region contains a large amount of lymphocytes. 
The malignant epithelial cells of the nasopharynx show no parakeratosis or 
comification and are frequently intermingled with lymphoid cells. 
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Electronmicroscopy studies defined that these cells are of squamous origin.(Prasad 
1974) 
According to the WHO classification system, NPC is classified 
histopathologically by the degree of differentiation into three major groups: Type I is 
keratinizing squamous cell carcinoma with the cells similar to those found in the 
other upper aerodigestive tract; Type II is non-keratinizing squamous carcinomas and 
type III includes undifferentiated carcinomas. The histological distribution of type I, 
II and III in Southern China is 2%, 3% and 95% respectively, with a great difference 
from North American, 25%, 12% and 63% respectively. 
2.3.1 Epidemiology of NPC 
NPC is an uncommon disease in most parts of the world, with an annual incidence 
rate less than 1 per 100,000 for both men and women.(1997) However, the disease 
occurs much more frequently in endemic regions such as southern China, northern 
Africa and Alaska.(Wei and Sham 2005) According to cancer incidence and 
mortality in Hong Kong from Hong Kong Cancer Registry, the crude incidence rate 
per 100,000 of male and female in 2003 is 16.0 and 5.3, ranking No. 6 and No. 16, 
respectively. 
EBV (Epstein-Barr virus) is human herpesvirus and infects more than 90% of 
the world's population. It is linked to the development of several malignancies 
including NPC.(Raab-Traub 2002) Specific EBV genes are consistently expressed 
with NPC tumors and even in early, dysplastic lesions. Mutiple studies have 
identified the transcription of the EBV-encoded small nuclear RNAs (EBERs), 
EBNAl, LMPl, LMP2 and the BamHI A transcripts in NPC samples. 
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Epidemiological studies have also linked childhood intake of locally 
consumed preserved food to NPC development in all groups of populations 
exhibiting high risk of NPC.(Yu and Yuan 2002) The diverse group of preserved 
foods might share common carcinogenic constituents or precursors. Actually the 
nitrosamines and EBV activating substances have been detected in a number of these 
preserved foods. Other recognized risk factors for NPC include cigarette smoking, 
occupational exposure to formaldehyde and wood dust.(Yu and Yuan 2002) 
2.3.2 Molecular genetic and epigenetic studies of NPC 
The initiation and progression of NPC involve accumulation of multiple genetic 
(amplification, deletion, translocation and mutation) and epigenetic (DNA 
methylation and histone modification) changes. These changes might contribute to 
the aberrant activation of oncogenes and inactivation of TSGs, subsequently lead to 
gain of growth advantage on the cell populations obtaining these changes. 
In the last a few decades, more and more technologies were developed 
working on genome-wide genetic alterations detection, from earlier cytogenetic 
analyses, spectral karyotyping and microsatellite marker analysis to the advanced 
technologies such as comparative genomic hybridization (CGH) and the latest high 
resolution array based CGH. By the multiple comprehensive genome-wide studies on 
NPC cell lines, xenografts and primary tumors, consistently high frequencies of 
genetic losses were observed on chromosome location 3p, 9, l lq, 13q, 14q and 16q, 
while recurrent chromosomal gains were located on chromosome 8 and 12.(Hui et al. 
1999; Chen et al. 1999; Chien et al. 2001; Lo et al. 2000) The most frequent regions 
showing loss and gain are 3p and 12, respectively. 
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Frequent hypermethylation of promoter region of cancer genes is an 
important feature of NPC. Several tumor suppressors, such as pi6 and RASSFIA, 
have been demonstrated to be inactivated mainly by aberrant promoter 
hypermethylation in NPC primary samples.(Kwong et al. 2002) The tumor 
suppressor activities of p i6 and RASSFIA in NPC were also proved. Ectopic 
expression of pi6 and RASSFIA in NPC cell lines lacking expression resulted in 
significant inhibition of cell growth, colony formation or tumor growth in nude 
mice.(Wang et al. 1999; Chow et al. 2004) A number of other tumor suppressors 
involved in multiple cellular functions were also identified to be disrupted by 
methylation. Examples are RARB2 in retinoid signaling pathway, EDNRB in 
endothelin-1 pathway (Lo et al. 2002)，BLU (Qiu et al. 2004) and GADD45G (Ying 
et al. 2005) in cell stress response, E-cadherin (Kwong et al. 2002) and TSLC-1 (Hui 
et al. 2003) involved in cell adhesion. Some new genes, such as PCDHIO of 
protocadherin family, was also characterized as functional tumor suppressor in NPC 
recently, but was frequently inactivate by promoter methylation.(Ying et al. 2006) 
However, critical common tumor suppressor p53, RB has rarely been found to be 
abnormally inactivated in NPC.(Sun et al. 1992; Sun et al. 1993) 
The information about oncogene alteration in NPC is still insufficient. By 
cytogenetic or array based CGH studies. Specific amplifications identified in NPC 
have implicated several putative oncogenes in NPC. These genes included BCL2, 
CCNDl, EGFR and MYC. Functional studies on some of these genes, such as 
CCNDl have demonstrated their oncogenic potential in NPC cells.(Hui et al. 2005) 
By candidate genes approach, the hypothesized involvement of ras gene mutation 
and Mdm gene amplification was excluded.(Yung et al. 1995; Qian et al. 1995) 
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2.3.3 NPC and chromosome l l q 
Some previous studies on chromosomal aberrations were performed on NPC and 
frequent chromosome 1 Iq genome sequence copy number losses were found. Hui et 
al examined a series of 20 primary NPC tumors with CGH. The results illustrated 
that 14 tumors (70%) exhibited loss of chromosome 1 Iq materials, and the common 
region of loss was mapped to 1 lq24-l lqter.(Hui et al. 1999) Fan et al. similarly 
examined ten NPC biopsies and found frequent (eight of ten cases) chromosomal 
losses on 1 lql4-qter.(Fan et al. 2000) Lo et al. performed high-resolution 
allelotyping on 27 microdissected primary tumors using 382 microsatellite markers 
and found the frequency of LOH on l lq is 74.1%.(Lo et al. 2000) Nevertheless, 
other studies found much lower frequency of loss of chromosome 1 Iq, 36% and 29% 
separately.(Fang et al. 2001; Chen et al. 1999) Fang et al. even mapped the most 
common region of loss at 1 lq21-qter and found this chromosomal alteration was 
detected with similar frequency in both early and advanced stage tumors, indicating 
that this alteration is an early event in NPC development.(Fang et al. 2001) Chien et 
al. also obtained similar results by performing CGH studies on 30 primary NPC 
tumors and found six cases with chromosomal llq23-qter region loss.(Chien et al. 
2001) 
2.4 ESCC 
ESCC is malignancy of the esophagus. The major symptom is dysphagia and weight 
loss, but with late onset. It is diagnosed with biopsy. There are two main forms of 
esophageal carcinoma (EC) according to histopathology, squamous cell carcinoma 
(ESCC) and adenocarcinoma, and each of them has distinct etiological and 
pathological characteristics. Up until the 1970s, even now in the EC endemic regions, 
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ESCC accounts for more than 90% of EC, with esophageal adenocardinoma being 
relatively rare. However, in the past three decades, the incidence of esophageal 
adenocarcinoma continues to increase in Western populations.(Daly et al. 2000) 
Other carcinomas, total representing less than 10% of esophageal cancers, include 
small cell carcinoma, mucoepidermoid carcinoma, adenoid cystic carcinoma 
etc.(Lieberman et al. 1994) 
The studies in my project focus on ESCC. There are multiple stages in the 
histological progression of ESCC, including the transition from normal squamous 
epithelium to hyperproliferative epithelium, low-grade dysplasia, intermediate-grade 
dysplasia, high-grade dysplasia/carcinoma in situ, and ultimately invasive 
ESCC.(Jankowski et al. 1999) 
The general prognosis of esophagus carcinoma is fairly poor because of 
difficulties in early detection. The overall survival rate at five year has increased 
from 4% in the 1970s to 14 % currently.(Enzinger and Mayer 2003) However, the 
five year survival rate exceeds 95% for stage 0 disease after complete surgical 
dissection of the tumor. Even for stage I disease, the expected rate could be 50-
80%.(Headrick et al. 2002; Reed 1999) These statistics data indicates an urge in the 
development of early detection. 
2.4.1 Epidemiology of ESCC 
Esophageal carcinoma is the sixth leading cause of death from cancer in the 
world. (Pisani et al. 1999) However, the incidence rate varies considerably among 
regions. The endemic areas include the so-called Asian esophageal cancer belt 
(extend from eastern Turkey through the southern former Soviet Union, Iraq, Iran 
and into western and northern China, Hong Kong, Japan), Southeastern Africa, 
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France and south America regions(Brazil and Bermudas).(Munoz 1993) Parts of the 
Henan, Shanxi and Hebei provinces in China show the highest incidence and 
mortality rates of ESCC in the world.(1975) These facts suggest that specific 
environmental factors play important roles in the etiology of this cancer. Meanwhile, 
an overall male to female incidence ratio 3:1 is also reported.(Pickens and Orringer 
2003) The risk increases with age, with a mean diagnosis age of 67 years old'. 
A variety of risk factors are associated with the development of ESCC. The 
major risk factors are tobacco smoking and alcohol consumption, (Kato et al. 2001) 
while a diet high in fruits and vegetables is associated with decreased risk. 
2.4.2 Genetic and epigenetic studies of ESCC 
Our knowledge on the molecular alterations about ESCC is still limited. Previous 
LOH studies suggested that loss of genomic materials on chromosomes 3p, 4p, 9q 
and 13q are involved in early stages of ESCC development while genes residing on 
3p24, 8p, 9p, l ip, 13q and 17p are involved in later stages.(Roth et al. 2001) The 
genetic alterations involved loci include the most critical tumor suppressors Rb(13q), 
p53(17p) and pl6INK4a(9p). Further RFLP assays based on PGR from 26 
informative ESCC tumors showed that LOH on Rb site was observed in 54% of 
samples.(Boynton et al. 1991) For p53, previous studies indicated that p53 mutations 
in ESCC occur in the early stage of carcinogenesis and are associated with tumor 
progression.(Kitamura et al. 1996) To date, more than 100 mutations have been 
compiled in the IRAC TP53 mutation database for ESCC.(01ivier et al. 2002) In 
addition, inactivation of the pl6INK4a gene in ESCC is also a common event, 
1. http://seer.cancer.gov/ 
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mainly caused by homozygous deletion and promoter hypermethylation.(Maesawa et 
al. 1996) 
For epigenetic studies, methylation of pl6INK4a, pl4ARF and RARB2 has 
been described in ESCC. The results revealed that inactivation of these genes by 
promoter hypermethylation was common mechanism in the pathogenesis of ESCC. 
(Nie et al. 2002; Wang et al. 2003) 
2.4.3 ESCC and chromosome l l q 
A plenty of previous observations suggest that the tumor genesis of ESCC is 
correlated with genetic aberrations in l lq. A Japanese group applied CGH analysis 
to 36 ESCC specimens and found that seven of them showed copy number loss in 
1 lq22-qter.(Tada et al. 2000) A Taiwan group checked the chromosomal aberrations 
of 46 tumor samples from ESCC and got similar result, 37% of those samples were 
found losses on chromosome l lq and the minimal overlapping region was 1 lq23-
qter. (Yen et al. 2001) These two groups both found that deletion of 1 Iq was linked 
to lymph node metastasis and is a significant prognostic factor. Notably, another 
group in USA found much higher frequency (59%) of chromosome loss in l lq, also 
by CGH analysis.(Pack et al. 1999) 
2.5 Chromosome l l q and other carcinomas 
2.5.1 Breast Cancer 
Frequent allelic deletions (42-54%) at llq24.1-25 were observed in a subset of 
sporadic early-onset breast cancer. This kind of cases usually showed no linkage to 
either BRCAl or BRCA2 (generally BRCAl and BRCA2 account for only 15%-20% 
of breast cancer cases that cluster in families and less than 5% of breast cancer cases 
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overall). It was also found that 1 lq25 deletions in breast cancer were associated with 
progression of the disease and also tended to be associated with poorer outcome in 
patients with early-onset breast carcinomas. Recently, a candidate TSG BCSC-1 has 
been identified located 10 Kb centromeric to the marker D11S1328 within the 4.6 
Mb region of 1 lq23.3-24.1. Some other candidate TSGs like CHKl, PIGS, and 
P53AIP1 have already been identified distal to the deletion region and a possible 
involvement of these genes in the breast carcinoma has been suggested. In a very 
recent study on ovarian tumors, a candidate TSG, OPCML, has been isolated from 
llq25. The role of this gene in breast carcinoma needs to be elucidated, as a few 
studies have indicated the importance of this region in earlyonset breast 
tumors.(Chunder et al. 2004; Gentile et al. 2001) 
2.5.2 Ovarian Cancer 
For ovarian cancer, LOH on 1 Iq22.3-q25 was frequently found and associated with 
adverse clinical behavior. Inside two subregions appeared to be particularly 
important. The first one mapped close to D11S1340 (at 1 lq23.3) and the second one 
near D11S912 (at Ilq24-q25). Another study in ovarian cancer patients showed that 
LOH of a critical 8.5-Mb interval between D11S934 (133.07cM) and D11S1320 
(146.94 cM) occurred frequently and was associated with poor survival, suggesting 
the presence of putative TSGs around this region which act as a suppressor of 
ovarian cancer progression.(Launonen et al. 1998; Stronach et al. 2003) OPCML, 
locating at llq25, is an identified candidate ovarian cancer TSG.(Sellar et al. 2003) 
The human homeobox gene BARX2 is also associated with frequent loss of 
heterozygosity and adverse survival in epithelial ovarian cancer.(Sellar et al. 2001) 
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2.5.3 Neuroblastoma 
Loss of chromosome 1 Iq defines a subset of high-stage aggressive neuroblastomas 
under the evidence that there was a strong inverse correlation between lp36.23-
lp36.32 and 1 lq23.3-llq25 deletions. Deletions on Ip36.23-lp36.32 stand for 
another subset of neuroblastomas. The existence of TSGs on l lq has also been 
supported by functional evidence obtained by microcell mediated chromosome 11 
transfer (MMCT) experiments. Deletions on l lq are typically large and mapping 
efforts have thus far not lead to a well defined consensus region, which hampers the 
identification of positional candidate TSGs. The microarray examination of the 
expression patterns of hundreds of genes mapping to l l q did not identify the 
candidate TSGs that are targeted by LOH alterations on this chromosome. The l lq 
TSG, however, might not have a large enough change in expression to be detectable 
by microarray analysis, particularly if the tumorigenic effect is a consequence of 
haploinsufficiency. Loss of expression of this TSG nevertheless could have a 
profound effect on the expression of other genes, which is perhaps evidenced by the 
fact that a number of genes located throughout the genome have expression profiles 
that are associated with loss of l lq. In another study, the expression of six known 
genes located in distal llq25, which are HNT, OPCML, JAMS, THY28, ACAD8 and 
B3GAT1, was tested. Among them, HNT and B 3 GAT I were reported to be involved 
in neurite outgrowth and neural crest development. However, the expression of these 
genes was not found significantly altered in the microcell hybrids compared to the 
parental cell line. But the expression of HNT was found significantly higher in 
specific cell lines that were induced to differentiate (5 to 120 fold induction). (De et 
al. 2005; McArdle et al. 2004; Mosse et al. 2005) 
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2.5.4 Melanoma 
Large deletions of more than 44 cM have been identified on 1 lq22-25 by Dib et al.. 
In addition, Eleonora et al. identified multiple independent critical regions on this 
chromosome by use of homozygosity mapping of deletions (HOMOD) analysis. 
Small overlapping deletion regions were identified on chromosome 11 flanked by the 
markers AFM21 Ove3/D 11S990. These results suggested that at least six melanoma 
tumor-suppressor genes reside on chromosome 11: two on l i p and four within the 
llq22-25 region frequently deleted en masse in metastatic melanomas and other 
cancers.(Goldberg et al. 2000) 
2.5.5 Multiple Myeloma 
In a previous study, 108 multiple myeloma (MM) patients were studied using FISH 
and DNA probes mapping to chromosome bands lq21, 9q34, 1 lq25, 13ql4, and 
14q32. As a result, three subsets of tumors were defined: (1) MM+/+ (detection of 
+9q and +l lq ; 43.5% of cases), (2) MM+/- (+9q or +l lq; 21.3%), and (3) MM-/-
(neither +9q nor +l lq; 35.2%). The results revealed that frequent l l q aberrations 
were identified in MM.(Liebisch et al. 2005) 
2.5.6 Lung Cancer 
A fine deletion map of human chromosome 11 was constructed by analysis of DNA 
from 79 lung cancers patients. The analysis included 31 sequence-tagged-site 
markers that dotted chromosome 11. The results showed that three regions, 1 lpl2-
pl5, 1 lql2, and Ilql4-q24, were commonly deleted, indicating the possible 
presence of more than one TSG.(Iizuka et al. 1995) The potent antiangiogenic factor 
ADAMTS-8 was identified to be at least two-fold under-represented in 85% (28 out 
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of 33) of primary non-small-cell lung carcinomas (NSCLCs) and the following 
research elucidated that the tumor specific downregulation was associated with 
frequent promoter hypermethylation.(Dunn et al. 2004) 
2.6 Important candidate genes located at the project study l l q region 
2.6.1 ETSl 
Gene aliases: ETS-1\ EWSR2; FLJ10768. 
ETSl, the founding member of Ets transcriptional factor family, plays an 
important role in cell proliferation, differentiation, lymphoid cell development, 
transformation, angiogenesis, and apoptosis.(Dittmer 2003) It is able to activate the 
transcription of several proteases, including urokinase-type plasminogen activator, 
collagenase I (MMP-1), stromelysin I(MMP-3), and gelatinase B (MMP-9). ETSl 
has the unique DNA binding domain, the Ets domain. The DNA binding activity of 
ETSl is controlled by kinases and some other transcription factors. Some 
transcription factors, such as AML-1, regulate ETSl by targeting its autoinhibitory 
module. Others, such as Pax-5, alter ETSl DNA binding properties. Meanwhile, 
ETSl is located upstream of angiogenesis cascade and regulates angiogenesis 
through the induction of angiogenic growth factors (VEGF and HGF). Therefore, 
overexpression of ETSl is usually associated with cancer progression and poorer 
prognosis.(Alipov et al. 2005; Span et al. 2002; Watson et al. 1985) On the other 
hand, ETSl encodes two proteins, a 51 kDa protein (p51-ETSl) and a 42 kDa protein 
(p42-ETSl), by alternately spliced mRNA reserving or lacking exon seven. The two 
major ETSl isotypes have overlapping (both repressing the tumorigenic phenotype of 
epithelial cells) and certain different (only the p42-ETS 1 protein promoting apoptosis) 
biological properties. The experiment evidences are tumor cells expressing the higher 
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levels of ETS1 made smaller and fewer colonies in soft agar and showed reduced 
tumor incidence in nude mice. Furthermore, DLDl colon carcinoma cells undergo 
apoptosis in either low-serum or Fas antibody treatment following expression of p42-
ETSl, but not p51-ETSl.The proposed mechanism is that p42-ETS 1 protein rescues 
a defect of Fas-induced apoptosis in colon carcinoma through the up-regulation of 
ICE/caspase-1 gene expression.(Huang et al. 1997; Pei et al. 2005; Li et al. 1999; 
Suzuki et al. 1995) 
2.6.2 FLIl 
Gene aliases: EWSR2; SIC-1. 
FLIl is also a member of Ets transcription factor family. Both human and 
mouse FLIl encode two protein isoforms, p51(452aa) and p48(419aa), through 
alternative splicing.(Prasad et al. 1992) Sarrazin et al. found that synthesis of the two 
isoforms were initiated through the two different highly conserved in frame initiation 
codons, AUG +1 and AUG +100.(Sarrazin et al. 2000) 
FLIl binds to DNA in a sequence specific manner and the optimal consensus 
sequence recognized is ACCGGAAG/aT/c.(Mao et al. 1994) The target genes of 
FLIl including GATA-1 (Athanasiou et al. 2000)，Rb (Tamir et al. 1999) and Bcl-2 
(Pereira et al. 1999b), the first two were downregulated and the later one was 
upregulated. Aberrant activation of FLIl is involved in malignant transformation. 
This may act through inhibition of apoptosis (Yi et al. 1997), the block of terminal 
differentiation (Pereira et al. 1999a) and the acceleration of proliferation (Zochodne 
et al. 2000). 
FLIl has also been shown to be a target of proviral integration in F-MuLV-
induced erythroleukemia and subject to a translocation in human Ewing's sarcoma. 
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FLU is expressed at high levels in F-MuLV-induced erythroleukemias and to a lesser 
extent in FV-P/FV-A-induced erythroleukemias. The clinical relevance of FLIl 
becomes apparent in human Ewing's sarcoma in which FLU is the target of a 
characteristic chromosomal translocation of t(l I;22)(q24;ql2) and 95% of Ewing's 
sarcoma cases show positive EWS/ FLIl fusion products. (Spahn et al. 2003; Truong 
and Ben-David 2000) 
2.6.5 P53AIP1 
The P53AIP1 gene generates three isoforms (a, 6 and y) by alternative splicing, with 
peptides of 124, 86, and 108 amino acids separately. P53AIP1 is localized within 
mitochondria. Ectopically expressed P53AIP1 a and B, but not y, are shown to lead 
to apoptotic cell death through dissipation of mitochondrial A\|/m and release of 
cytochrome C from mitochondria. Further intensive study showed that P53AIP1 is a 
novel inducible target of p53 tumor suppressor and plays an important role in 
mediating p53-dependent apoptosis. Substitution of p53 Ser-46 might inhibit the 
ability of p53 to induce apoptosis due to failure of induction of P53AIP1 expression. 
P53AIP1 also interacts with bcl-2. Overexpression of bcl-2 blocks the proapoptotic 
activity of P53AIP1. (Matsuda et al. 2002; Nakamura 2004) 
2.6.4 RICS 
RICS is a neuron-associated GTPase-activating protein that may regulate dendritic 
spine morphology and strength by modulating Rho GTPase activity. 
2.6.5 BARX2 
Gene aliases: MGC133368, MGC133369 
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BARX2 is a member of the homeobox transcription factors, which are 
regulators of place-dependent morphogenesis and play important roles in controlling 
the expression patterns of cell adhesion molecules. Intensive studies of mouse Barx2 
showed that it is a regulator of N-CAM and LI-CAM expression. The CAMs 
molecules have been well recognized in cancer progression because the roles in 
epithelial-mesenchymal transition.(Jones et al. 1997; Meech et al. 1999) 
Human BARX2 has also been described as a TSG. Frequent LOH of a 
critical 8.5-Mb interval between D11S934 and D11S320 with BARX2 residing has 
been observed in epithelial ovarian cancer. Significant lower expression of BARX2 
was present in clear cell and endometrioid ovarian cancer compared to other 
histological subtypes. And the LOH accompanied BARX2 silencing is associated 
with poor survival. (Gabra et al. 1996) Furthermore, loss of BARX2 expression 
correlates with invasiveness in epithelial ovarian cancer, and ectopic expression of 
BARX2 inhibits the invasiveness of an ovarian cancer cell line. 
BARX2 can coordinate the expression of a network of genes that influence the 
growth of tumor cells. In a series of ovarian cancer cell lines, BARX2 expression 
showed a significant direct correlation with cadherin 6 expression. In OAW42, an 
ovarian cancer cell line that does not endogenously express BARX2, in vitro 
transfection of human BARX2 cDNA induced cadherin 6 expression. After 
transfection of BARX2 expression vectors into OAW42, the cells abilities to invasion 
Matrigel, to migrate to a collagen IV haptotactic signal, and to adhere to collagen IV-
coated plates were significantly inhibited. Moreover, transfection of BARX2 into 
OAW42 caused an accumulation of cells in the S phase and thus induced cell cycle 
delay. 
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These data demonstrated that BARX2 has functional suppressor properties in 
ovarian cancer cells, loss of BARX2 expression is involved in tumor progression. 
(Sellar et al. 2002; Sellar et al. 2001) 
2.6.6 ST14 
Gene aliases: HAI; MTSPl; SNC19; MT-SPl; MTSP-1; PRSS14; TADG-15 
The protein encoded by this gene is an epithelial-derived, integral membrane 
serine protease. This protease forms a complex with the Kunitz-type serine protease 
inhibitor, HAI-1, and is found to be activated by sphingosine 1 -phosphate. This 
protease has been shown to cleave and activate hepatocyte growth factor/scattering 
factor, and urokinase plasminogen activator, which are known to play important roles 
in tumor development. The expression of this protease has been associated with 
breast, colon, prostate, and ovarian tumors, which implicates its role in cancer 
invasion and metastasis. In normal human tissues, high ST 14 expression levels were 
observed in the kidney, pancreas, prostate, small intestine and colon; moderate ST 14 
expression levels were observed in the placenta, lung, liver, spleen thymus, testis and 
peripheral blood lymphocytes; and extremely low expression levels were observed in 
the heart, brain, skeletal muscle and ovary. In tumor cell lines, colorectal cancer cells 
SW480, SW620, SWl 116 and Colo205, breast cancer cell Bcap37 and gastric cancer 
cells MKN28 and SGC7901 showed high levels of ST 14 expression; cervical cancer 
cell HeLa-S3, lung cancer PAA, oral epithelial cancer cell KB and lymphoma cell 
Raji showed moderate levels of ST 14 expression; and tongue squamous cancer cell 
Tca8113, leukemia cells HL-60, K562, MOLT-4, lung cancer cell A549 and 
melanoma cell G361 showed very low levels of ST 14 expression. ST 14 may prove to 
be a useful diagnostic tool for the early detection of recurrence/persistence after 
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standard treatment or as a novel molecular target for therapy of some kinds of 
carcinoma.(Cao et al. 2001; Oberst et al. 2002; Oberst et al. 2001; Santin et al. 2003; 
Sun et al. 2004; Tanimoto et al. 2005) On the other hand, Norihiro Sato et al. 
identified potential aberrant methylation in pancreatic cancer through treatment with 
the demethylating agent. The results showed that ST 14 was methylated in 10% of 42 
primary pancreatic tumors and 9% of 22 pancreatic cancer cell lines.(Zhang et al. 
1998; Sato et al. 2003) 
2.6.7 ADAMTS8 
Gene aliases: ADAM-TS8, FLJ41712, METH2 
ADAMTS8 encodes a member protein of the ADAMTS (A Disintegrin And 
Metalloproteinase with ThromboSpondin motifs) protein family. Until now 19 
ADAMTS genes, numbered 1-10 and 12-20, have been characterized. Members of 
this family share several distinct protein modules, including a propeptide region, a 
metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 
(TS) motif, while different members are distinguished by the number of TS motifs 
and some unique C-terminal domains. (Porter et al. 2005) The ADAMTSs have 
varying function in extracellular matrix degradation, organogenesis, proteoglycans, 
hemostasisand and inhibition of angiogenesis.(Tang 2001; Porter et al. 2004) 
Among the ADAMTS protein family, ADAMTS 8 is a potent inhibitor of 
angiogenesis (Iruela-Arispe et al. 1999) and a number of disorders have been mapped 
in the vicinity of this gene. ADAMTSS encompasses a 24 kb genomic region at 
chromosome l lq 25.(Georgiadis et al. 1999) The mRNA full length is 4028 bp, 
composed of 9 exons, which encodes an 890 aa, secreted protein with an N-terminal 
signal peptide. Northern blot analysis data illustrated highest expression of 
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ADAMTS8 transcript in adult and fetal lung, with lower expression in brain, placenta, 
heart, and stomach, as well as fetal brain and kidney.(Vazquez et al. 1999) 
For ADAMTS8, the conserved domains (motifs) contain ADAM-TS Spacer 1; 
Thrombospondin, type I; Disintegrin; Peptidase M，neutral zinc metallopeptidases, 
zinc-binding site; Peptidase M12B, ADAM/reprolysin; Peptidase M12B, propeptide; 
Thrombospondin, subtype 1. Accordingly, the molecular functions contain heparin 
binding; integrin binding; low affinity phosphate transporter activity; metal ion 
binding; metalloendopeptidase activity; zinc ion binding activity ^. Interspecific 
backcross study mapped the mouse ADAMTS8 gene to chromosome 9 in a region 
showing homology of synteny with human llq23-qter. Human and mouse 
ADAMTS8 share 84% nucleotide identity and 76% amino acid identity by comparing 
the cDNA as well as the predicted polypeptides.(Georgiadis et al. 1999) 
It is proved that ADAMTS8 disrupted VEGF-induced angiogenesis in vivo 
and in vitro more efficiently than THBSl or endostatin by functional chorioallantoic 
membrane (CAM) assay.(Vazquez et al. 1999) The antiangiogenic activity might be 
mediated by the first C-terminal TS repeat containing common GWQRRL/TVECRD 
motifs. This motifs specific repeat is present in both ADAMTS8 and ADAMTS1, but 
absent in any other ADAMTSs.(Porter et al. 2005) Furthermore, AD AMTS 8 was 
shown to inhibit endothelial cell proliferation in vitro. (Vazquez et al. 1999) 
Downregulation of ADAMTS8 expression in primary non-small-cell lung 
carcinomas (NSCLC) is a frequent event. ADAMTS8 was identified to be at least 
two-fold under-represented in 85% (28 out of 33) of NSCLCs in a dual-channel 
cDNA microarray analysis. This observation had been validated in an independent 
series of NSCLCs and adjacent normal tissues by comparative multiplex RT-PCR. It 
1. http://genome.cse.ucsc.edu 
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was proposed that epigenetic mechanisms are involved in the downregulation 
because abnormal hypermethylation was found in 67% of the adenocarcinomas and 
50% of squamous cell carcinomas.(Dunn et al. 2004) 
The expression of ADAMTS8 in high-grade gliomas and other brain tumors 
was also studied. The results showed high percentage of downregulation in both 
mRNA level and protein level in the brain tumor tissues compared to paired normal 
tissues. However, ADAMTS8 promoter methylation was present in only one out of 24 
brain tumors.(Dunn et al. 2006) 
It was reported that ADAMTS8 was consistently downregulated in breast 
carcinomas with respect to nonneoplastic mammary tissue, irrespective of the 
heterogeneity of the samples and the tumor type or grade.(Porter et al. 2004) 
Furthermore, in breast carcinoma patients, presence of ADAMTS8 expression was 
associated with poorer prognosis for both OS (overall survival) and RFS (relapse-
free survival). It suggest that ADAMTS8 might perform different functions between 
normal tissue and cancer cells.(Porter et al. 2006) 
2.6.8 ADAMTS15 
ADAMTS15 encodes another member protein of the ADAMTS protein family. 
ADAMTS15 has emerged as being an independent predictor of survival, with RNA 
expression levels significantly lower in grade 3 breast carcinoma compared with 
grade 1 and 2 breast carcinomas.(Porter et al. 2004) Further RNA expression analysis 
by real-time PCR on a different cohort of 229 patients with breast cancer has 
confirmed ADAMTS 15 as a predictor of prolonged relapse-free survival (RFS) while 
lower ADAMTS 15 lever was associated with poorer prognosis.(Porter et al. 2006) 
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2.6.9 HNT 
Gene aliases: NTM; MGC60329 
This gene encodes a member of the IgLON {OPCML, HNT, LSAM? and 
NEGRI) family of immunoglobulin (Ig) domain-containing glycosylphosphatidyl-
inositol (GPI)-anchored cell adhesion molecules. Two members of this family 
{OPCML (Sellar et al. 2003) and LSAMP (Chen et al. 2003)) have been reported to 
be functional tumor suppressor but may be inactivated through CpG island 
hypermethylation in promoter region. Ntougkos et al investigated the expression of 
the four members in a panel of 11 normal human ovaries and 57 epithelial ovarian 
cancer patient tumor samples and found that only HNT showed an elevated 
expression in tumor samples compared to normal samples while the other three 
showed reduced expressions. Furthermore, the expression elevation of HNT was 
shown to be correlated with serious histologic type carcinoma. (Ntougkos et al. 2005) 
Additionally, the expression of HNT mRNA in brain tumors was also studied. 
However, the results showed that HNT was downregulated in the three nervous 
system tumor types checked.(Liu et al. 2004) The HNT protein may promote neurite 
outgrowth and adhesion via a homophilic mechanism. Moreover, HNT is closely 
linked to a related family member, opioid binding protein/cell adhesion molecule-
like (OPCML).(Ntougkos et al. 2005) 
2.6.10 OPCML 
Gene aliases: OPCM; OBCAM 
OPCML is an identified candidate ovarian cancer TSG at the 1 lq25.(Sellar et al. 
2003) 
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Chapter 3: Materials and Methods 
3.1 Cell lines and primary tumor samples 
A series of carcinoma cell lines were used in my study, including nasopharyngeal 
(NPC, Table 3-l)(C666-l, CNEl, CNE2, HKl, HNEl, and HONEl), 
esophageal(ESCC)(ECl, EC 18, EC 109, HKESCl, HKESC2, HKESC3, KYSE30, 
KYSE70, KYSE140, KYSE150, KYSE180, KYSE270, KYSE410, KYSE450, 
KYSE510, KYSE520，SLMTl and COLO-680N), hepatocellular(HCC)(Hep3B, 
HepG2, HUHl, HUH4, HUH6, HUH7, Mahlavu, PLC/PRF/5, SNU387, SNU398, 
SNU423, SNU449 and SNU475), gastric(KatoIII, YCCl, YCC2, YCC3, YCC6, 
YCC7, YCC9, YCCIO, YCCll , YCCl6 and SNU719), breast(BT549, MB231, 
MB468, MCF-7, T47D，SK-BR-3, YCC-Bl，YCC-B3 and ZR-75-1), lung(A427, 
A549，H292, H358 and H1299), cervical(C33A, CaSki, Hela and SiHa), 
colorectal(HCT116, HT-29, Lovo and SW480), renal(RCC)(A498, Caki, HH050, 
HH244, RCC52, RCC98 and 7860) and prostate (PCS, LNcap and Dul45). Eight 
immortalized normal epithelial cell lines (NP69, NEl, NE3, Het-IA, HMEC, 
HMEpC, HEK293 and RHEK-l)(Hukku et al. 1997; Tsao et al. 2002) with many 
characteristics of normal epithelial cell were also used. HCT116 cell lines with 
double genetic knock-out of DNA methyltransferases DNMTl and DNMTSB (DKO, 
gift of Bert Vogelstein, Johns Hopkins) was used as a genetic demethylation cell line 
model. All these cell lines were routinely maintained in the lab. 
Various human normal tissues and primary tumors archived in the Lab were 
also used. Human normal adult and fetal tissue RNA samples were purchased 
commercially (Stratagene, La Jolla, CA, USA & Ambion Inc., Austin, TX, USA). 
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Table 3-1 Characteristics of NPC cell lines 
Name Histological Type EBV References 
C666-1 Undifferentiated carcinoma + (Cheung et al. 1999) 
CNEl Well-differentiated squamous cell carcinoma - (Teng et al. 1996) 
CNE2 Poorly-differentiated squamous cell carcinoma - (Sizhong et al. 1983) 
HKl Well-differentiated squamous cell carcinoma - (Huang et al. 1980) 
HNEl Poorly- differentiated squamous cell carcinoma - (Glaser et al. 1989) 
HONEl Poorly- differentiated squamous cell carcinoma - (Glaser et al. 1989) 
3.2 Cell line demethylation treatment 
Drug 5-aza-2‘-deoxycytidine is a kind of DNMT inhibitors. It could trap the DNMT 
enzyme through forming a covalent complex with the DNA, resulting in a loss of 
DNA methylation with each round of cell division. (Juttermann et al. 1994) 
Trichostatin A is a drug with histone deacetylase (HDAC) inhibition activity, and it 
usually does not reactivate cancer genes when used alone. However, trichostatin A 
does exert additive or synergistic effects when used as a combination of 5-aza-2'-
deoxycytidine. (Cameron et al. 1999) 
Cell lines were treated with 5-aza-2'-deoxycytidine(Sigma-Aldrich 
Corporation, St. Louis, MO, USA) alone or treated combining 5-aza-2'-
deoxycytidine and trichostatin A(Cayman Chemical Company, Ann Arbor, MI). For 
cell lines treated with 5-aza-2'-deoxycytidine, cells were diluted to 10^  per mL and 
allowed to grow overnight. Then 5-aza-2'-deoxycytidine was added to a final 
concentration of 1 to 50 |iM. The cells were allowed to grow with changing the 5-
aza-2‘-deoxycytidine and medium each day. Three days later, the cells could be 
harvested for DNA and RNA extraction. For cell lines treated combining 5-aza-2'-
deoxycytidine and trichostatin A, the cells were treated with 5-aza-2‘-deoxycytidine 
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for three days as described above and subsequently with trichostatin A (final 
concentration 100 ng/mL) for 24 hrs. 
3.3 DNA and RNA extraction from cell lines and tissues 
Total DNA and RNA were extracted from the washed cell pellets or fresh/frozen 
tumor tissues using the TRI® Reagents (Molecular Research Center, Inc. Cincinnati, 
OH, USA) which apply the "a single step" method for the simultaneous preparation 
of DNA and RNA. The reagent facilitates the immediate and effective inhibition of 
RNase activity by combining phenol and guanidine thiocyanate in a mono-phase 
solution. Guanidine thiocyanate is a strong inhibitor of RNase because it is one of the 
most powerful commonly used protein denaturants. The following points constitute 
the main principle of DNA, RNA isolation. The sample is Ivsed in TRI® REAGENT 
and the homogenate is separated into aqueous and organic phases by chloroform 
addition and centrifugation. RNA remains in the aqueous phase and is precipitated by 
addition of isopropanol. Most of DNA remains in the interphase and it is precipitated 
with EtOH. 
The extraction procedure followed the Manufacturer's protocol. 
(Chomczynski 1993) In brief, the cultured cells were directly lysed by TRI reagent. 
For monolayer cells, 1 mL TRI was added to per 10 cm^ culture dish area and the 
cell lysate was passed several times through a pipette. For suspension cells, 3 mL 
TRI was added to per 10 X 10^ cell pellet and the mixture was pipetted repetitively to 
lyse cells. For the fresh or frozen tissues, 1 mL TRI was added to per 50-100 mg of 
tissue and the mixture was homogenized with a glass homogenizer. The volume of 
the TRI reagent used for lysis was standardized as 1 vol. The homogenate was 
transferred to a microcentrifuge tube and vortexed gently. After incubation at room 
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temperature for 5 min, 0.2 vol. of chloroform was added to the homogenate and 
mixed well by vortexing for 15 sec. The mixture was incubated for 3 min at room 
temperature and the aqueous phase was separated from the organic phase by 
centrifugation at 12,000 g for 15 min at 4 °C. For RNA isolation, the colorless upper 
aqueous phase was transferred to a fresh tube. A half vol. of isopropyl alcohol was 
added and the mixture was incubated for 10 min at room temperature. The RNA 
pellet was obtained by centrifugation at 12,000 g for 15 min at 4 °C and subsequent 
wash with 1 vol. of 75% EtOH. The RNA pellet was air dried and dissolved with 
RNAsecure™ Re suspension Solution (Ambion) or RNA Storage Solution (Ambion) 
on ice for several hrs with intermittent vortexing. The RNA was kept at -80 °C for 
further use. For DNA isolation, the leftover aqueous phase was completely removed 
firstly. Then 0.3 vol. of 100% EtOH was added to the remaining interphase and 
organic phase. The samples were mixed by inverting for several times and were 
incubated at room temperature for 3 min. The DNA pellet were obtained by 
centrifugation at 2,000 g for 5 min at 4 °C and the supernatant was removed carefully. 
The pellet was washed twice with 1 vol. of washing solution consisting of 0.1 M 
sodium citrate in 10% EtOH. For each wash procedure, after the DNA pellet was 
stored in the washing solution for 30 min at room temperature with intermittent 
mixing, the mixture was centrifuged at 2000g for 5 min at 4 °C. Then the DNA pellet 
was re-suspended in 1.5-2 vol. of 75% EtOH. The mixture was incubated for 10-20 
min at room temperature with intermittent mixing and centrifuged at 2,000 g for 5 
min at 4 °C. The DNA pellet was air dried at room temperature and dissolved with 
8mM NaOH (500 [iL for 10 X 10^  cells) at 4 °C overnight. Finally the pH was 
adjusted to 8.0 with HEPES (Gibco BRL) and the DNA samples were kept at 4 � C 
for further use. 
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The concentration and purity of both RNA and DNA was approximately 
estimated by a spectrophotometer (Beckman DU650). The nuclear acid samples were 
usually diluted by 60 times using 0.01 M Tris-HCl (pH 8.0). The concentration was 
determined by measuring the optical density (OD) value of the diluted sample at the 
wavelength 260 nm. The purity was estimated by the OD value ratio (260/280) at 
different wavelength. 
3.4 Semiquantitative RT-PCR 
Reverse transcription reaction was performed as the following by using the 
GeneAmp RNA PGR kit (Applied Biosystems, Foster city, CA, USA). The RNA 
supplemented with DEPC treated water was heated at 90 °C for 5 min to unzip the 
secondary structure and was kept on ice for use. For each 1 |xg of total RNA, it was 
primed with 50 pMol of random hexameric primers and reverse transcribed into 
cDNA in a 20|liL reaction volume containing 50 U of MuLV reverse transcriptase 
(50U/^1, Applied Biosystems), lOX PGR buffer n(500 mM KCl, lOOmM Tris-
HCl, PH=8.3), 100 nMol MgCh, 20 nMol of each dNTPs (dATP, dCTP, dGTP and 
dTTP), and 8 U of RNase inhibitor(40U/|Lil, Roche Applied Science, Germany). The 
reverse transcription was carried out at 42 °C for 60 min followed by incubation at 
99 °C for 5 min, then 5 � C for 5 min. The RT product was kept at -20 °C (or -80 °C 
for long time storage) for use. 
Semiquantitative RT-PCR was performed by using AmpliTaq gold (Applied 
Biosystems, Foster city, CA, USA). The forward and reverse primer pairs for RT-
PCR were usually designed on coding sequence region of exon 1 and exon 2 of the 
gene separately, spanning introns to avoid amplification of genomic DNA. Product 
size between 150 and 300 bp was preferred. The PCR was carried out in an MJ DNA 
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Engine Dyad® Thermal Cycler (MJ research, Waltham, MA). The program started 
with an initial denature step at 95°C for 10 min to activate the polymerase enzyme, 
followed by 36 — 38 cycles (94°C for 30s, 55°C for 30s and 72°C for 30s) of 
amplification, with a final extension step at 72°C for lOmin. All of the PGR reaction 
products were used for agarose gel detection. The agarose gel was prepared with 
agarose powder (Cambrex Bioscience, USA) at 1.8 % (w/w) in IX TAE buffer, 
supplemented with 5|il of EtBr. DNA samples were loaded into the wells of the gel 
with the addition of 6X loading buffer to a final concentration of IX, and 
electrophoresis was usually carried out at constant voltage of 120V for 25 min in a 
gel tank with appropriate volume of IX TAE buffer. The PGR bands were stained 
with EtBr and visualized under UV illumination (Biorad), photographed, and 
quantitated with the EagleEye digital gel documentation system and the supplied 
densitometry software (EagleSight Software, version 3.2, Stratagene, La Jolla, CA). 
Human house keeping gene GAPDH 观s used as the positive controls and also the 
control for RNA integrity, and 25 cycles of RT-PCR amplification was used. The 
GAPDH primers were designed according to the GAPDH mRNA sequence 
(GenBank accession no. NM_002046). 
Each PGR reaction contains 1 pL lOX PCR buffer O, 25 nMol MgCh, 7.5 
pMol F/R primers, 0.3U AmpliTaq gold and 0.125 |Lig RT product (2.5 |iL, including 
dNTPs remained in the Reverse transcription reaction). The final volume for each 
reaction was 12.5 ^L. For PCR reactions with 5% (v/v) DMSO, 0.625 DMSO 
was supplemented to the reaction mixture and two more amplification cycle was 
added. 
3.5 DNA bisulfite treatment 
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Bisulfite conversion of DNA, firstly introduced by Frommer and colleagues in 1992, 
remains the most widely used method to study DNA methylation. This method is 
especially suitable for study on limit amount of starting material. The bisulfite 
treatment of DNA converted unmethylated cytosine (but not methylated cytosine) to 
uracil, which could be further converted to thymidine during the subsequent PCR 
procedure. As a consequence, this treatment gave sequence differences between 
methylated and unmethylated DNA and this information could be used in the further 
methylation analysis. 
The complete conversion of unmethylated cytosine to uracil consists of three 
steps: (1) Reversible sulfonation of cytosine residues to cytosine-6-sulfonate. This 
reaction is favored at low PH and low temperature. (2) Irreversible hydrolytic 
deamination of cytosine-6- sulfonate to uracil-6-sulfonate. This is favored at higher 
concentration of sodium bisulfite and higher temperatures. The optimized PH is 
between 5 and 6. (3) Reversible desulfonation of uracil-6-sulfonate to uracil. This 
elimination reaction is favored at higher PH. 
Briefly, genomic DNA was extracted as described previously in 3.3 and 3.4. 
For each 5 |Lig of genomic DNA in 30|LIL of TE buffer, it was denatured without using 
restriction endonuclease by adding 3.3|LIL of 3M freshly prepared NaOH to a final 
concentration of 0.3M, and incubating at 37°C for 15 min. The denatured DNA was 
mixed with 333|LI1 of bisulfite solution. Bisulfite solution was prepared by mixing 
1.82g sodium metabisulfite (Sigma-Aldrich Corporation, St. Louis, MO, USA) with 
2.8mL water and 430 [iL 3M NaOH. After dissolving by inverting the tube gently, 
1/19 volume (210 |liL) of lOmM hydroquinone (Sigma H7148) was added to the tube 
to make a final volume of 4mL. pH of the solution was checked to be around 5.0 to 
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5.2. Bisulfite treatment was carried out at 55°C for 4 hrs in dark. The reaction 
mixture was heated to 95°C for 3 min every hour during the incubation period. 
After bisulfite reaction, the DNA was purified by either the Wizard DNA 
Clean-up System (Promega) or the QIAEX II Gel Extraction Kit (Qiagen, 
Germantown, MD, USA). For the Promega Wizard DNA clean-up system, bisulfited 
DNA was purified according to the manufacturer protocol and eluted in 50|il pre-
warmed TE buffer. The DNA was then treated with 0.3M NaOH at 37�C for 15 min. 
Subsequently, 27.78|LI1 of 9M NH4OAC (pH7.0) was added to a final concentration of 
3M to neutralize the reaction mixture. DNA was then precipitated by 3 volumes 
(250|al) of EtOH at -20�C overnight, followed by centrifugation at 20,000g /15 min. 
After discarding the supernatant, the pellet was washed with 70% EtOH by 
centrifugation for 10 min. Finally, the pellet was air dried and dissolved in TE buffer 
(l |ig in 20|il). Bisulfited DNA was stored at -20°C for further use. For QIAEX II gel 
extraction kit, the bisulfite reaction mixture was transferred into a new tube with 
ImL QXI and 40|il of QXII was added. The mixture was allowed to rotate for 1 hour 
at room temperature. The DNA was purified according to the Qiaex II protocol. The 
purified DNA was dissolved in 50|xl TE buffer for 5 min at room temperature. It was 
then treated with 0.3M NaOH at 37°C for 15 min. The mixture was then neutralized 
by adding 27.78}xl of 9M NH4OAC (pH7.0) to a final concentration of 3M. Then the 
pH was corrected to be lower than 7.0 with 50|xl of 3M NaOAc (pH5.2). After that, 
the DNA was purified by using the Qiaex II kit again. The DNA was eluted in 100|LI1 
TE buffer and was stored at -20°C before use. 
In this reaction, the unmethylated cytosine will remain unconverted if it is in 
double stranded DNA. Thus the DNA should be completely denatured prior to 
treatment with bisulfite to avoid false positive result in further analysis. 
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3.6 Promoter analysis and identification of 5' CpG islands of target genes 
The gene core promoter regions are usually located at the neighboring regions of 
exon 1. In my project, the DNA sequences (2000 bp upstream and downstream of 
exon 1) were retrieved from the human genome browser gateway\ Whether the 5' 
CpG islands were present around the core promoter regions of the genes were then 
identified by the online CpG Island Searcher program^ or the GeneTool Lite 1.0 
(Biotools Inc., Edmonton, Alberta, Canada). The criteria of a 5' CpG island was: GC 
content > 55%, ratio of observed CpG / expected CpG > 0.65, minimum length of 
SOObp and minimum gap length of 100 bp between adjacent islands. (Takai and 
Jones 2002) Some genes (such as BARX2) core promoter regions have been well 
characterized using promoter luciferase reporter assay. (Meech et al. 2003) The 
critical transcription factor (TF) binding sites were also predicted in the region using 
TF searching program TFSEACtf. These analyses helped to identify the promoter 
region more accurately. 
3.7 Methylation-Specific PCR (MSP) 
For MSP, the bisulfite-treated DNA was amplified with either a methylation-specific 
primer set or an unmethylation-specific primer set. The different primer sets are 
specifically designed to distinguish the sequence between the methylated and 
unmethylated DNA. The PCR was performed for 40 cycles using AmpliTaq gold 






Each PGR reaction contained 1.25 |LIL lOX PGR buffer O, 25 nMol MGCL2, 
2.5 nMol of each dNTPs (dATP, dCTP, dGTP and dTTP), 7.5 pMol F/R methylation 
specific primer, 1.25U AmpliTaq gold and about 0.012 |Lig bisulfite genomic DNA. 
The final volume for each reaction is 12.5 |aL. 
The PGR was carried out in an MJ DNA Engine Dyad® Thermal Cycler. The 
program started with an initial denature step at 95°C for 10 min to activate the 
polymerase enzyme, followed by 40 cycles (94�C for 30s, 58/60�C for 30s and 72�C 
for 30s) of amplification, with a final extension step at 72°C for 3 min. All of the 
PGR products were analyzed on 2.0% agarose gel containing EtBr and photographed 
under UV illumination (Biorad). 
3.8 Bisulfite Genomic Sequencing (BGS) 
The DNA was bisulfite treated as described above and the bisulfite treated DNA was 
amplified using the strand specific BGS primers around the interested target 
sequence fragment. These primers are specific to the bisulfite treatment converted 
DNA sequence. To obtain higher ligation efficiency in the next TA cloning step, a 
more G nucleotide was added at the 5' end of each primer. 
3.8.1 BGS PGR reaction 
The BGS PCR reaction was performed similarly to MSP except that the final 
extension step of BGS PCR was extended to 60 min. The expected PCR product in 
gel slices were excised under UV (long wave) and isolated from the gel. The DNA 
were purified using SpinX column(the final yields range from 30% to 80%) by 
centrifuging the gel slices for 1 min at 20,000g and collecting the spin down products. 
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3.8.2 TA cloning of the PGR products into the sequencing vector 
The extracted PGR products were cloned into pCR4.0-TOPO vector with TOPO TA 
cloning kit for sequencing (Invitrogen, Carlsbad, CA, USA). The principle of the kit 
is: The linearized plasmid vector is supplied with single 3' deoxythymidine (T) 
residue overhanging and topoisomerase covalently bound. The PGR products were 
added an overhanging single deoxyadenosine (A) to the 3' ends because of the 
nontemplate-dependent terminal transferase activity of the Taq polymerase used in 
BGS PGR. Topoisomerase could cleave the phosphodiester backbone after 5'-
CCCTT in one strand and the energy from the broken bond is conserved by 
formation of a covalent bond between the 3' phosphate of the cleaved strand and Tyr-
274 residue of topoisomerase. The phospho-tyrosyl bonds between the DNA and the 
enzyme can subsequently be attacked by 5' hydroxyl of the PCR product DNA and 
form phosphodiester bond again. This reaction allows PCR products to ligate with 
the vector efficiently. Vector pCR4.0-TOPO allows direct selection of recombinants 
because the vector contains the lethal E.coli gene, ccdB, which can be fused to C-
terminus of the LacZa fragment. Cells containing non-recombinant empty vector 
would be killed upon plating. However, successful ligation of a PCR product could 
disrupt the expression of the LacZ a — ccdB gene and permit the growth of 
transformed cells. Therefore, blue/white screening is not required. 
The TOPO cloning reaction and the subsequent transformation was 
performed as below. For BGS PCR product showing strong bands under UV 
detection, 2 }xL of purified PCR products was mixed with 0.5 fiL salt solution 
supplied in the kit and 0.5 ^L vector gently. For products with weak bands, 4 |LIL 
PCR product was mixed with 1 [lL salt solution and 0.5|LIL vector accordingly. Then 
the mixture was incubated for 15 min at room temperature and transferred into 50 \iL 
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of chilled DH5 a competent cells with gentle mixing. After incubation on ice 
for 20 min, the cells were heat shocked at 42 °C for 60 seconds without shaking and 
incubated on ice immediately for 3 min. Then 100 \iL of S.O.C. medium (room 
temperature) was added to the tube. The tube with tightly capping was shaken 
horizontally at 37 °C at a rate of 200 rpm for 45 min. Finally, all of the solution in 
the tube was spread on a 37 °C prewarmed LB agar plate with ampicillin or 
kanamycin and the plate was incubated at 37 °C overnight. Hundreds of colonies 
should appear if this TOPO cloning reaction is efficient. 
3.8.3 Plasmid mini-preparation on 96-well plate 
For each plate, about 6 colonies were selected for subsequent plasmid DNA 
extraction and sequencing. The plasmid was cultured and extracted in a 96 well plate. 
For the bacteria inoculation, 1.2 mL LB medium supplemented with Ampicillin or 
kanamycin (0.1 ^g Ampicillin or 0.05 |xg kanamycin for 1 mL LB media) was 
aliquoted into each well in the plate. Subsequently, each fresh colony was picked into 
each individual corresponding well using the sterile yellow tip. After the 96 wells 
were inoculated, the content of each well was briefly mixed using the 8-tip multi-
pipette and all the yellow tips were thrown away. Then the plate was covered and 
incubated at 37 °C overnight with shaking at a speed of 250 rpm. 
The plasmid mini preparation was performed on a 96 well plate as described 
below. Firstly, 50 |iL bacteria of each well were transferred into the corresponding 
well of a new sterile 350 |iL 96 well plate for storage. The storage plate was kept at 4 
°C. The rest of bacteria culture was spun at lOOOg for 10 min. The supernatant was 
poured out carefully. Then the bacteria were lysed with alkaline lysis solution as the 
following. Firstly the bacteria pellet was resuspended with 150 |LIL ice cold Solution I. 
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After 10 min of incubation at room temperature, 300 i^L Solution II was added. The 
plate was gently shaken for 3-5 min until the mixture became clear. Then the lysate 
contained plate was transferred on ice and 225 |xL ice cold Solution III was added 
immediately, followed with a mixing and incubation at room temperature for 5 min. 
To this procedure, the plasmid was released into the solutions. To separate the 
solutions with the debris of the bacteria, the plate was centrifuged at lOOOg/15 min 
and 520 |xL clear suspensions for each well were carefully transferred to two new 
500 |LIL 96-well plates. The two plates were centrifuged at 2000g for another 15 min 
at room temperature and 500 |LIL suspensions were transferred to another 1 mL 96-
well plate. Then the ethanol precipitation was used to recover the plasmid. Firstly 
300 fiL isopropanol was added into each well. The mixture was incubated for 15 min 
at room temperature and centrifuged at 2500g/20min. Then the supernatant was 
poured out and the tiny pellet containing the plasmid DNA was remained in the plate. 
The pellet was washed with 700 |xL of 70% EtOH. The mixture was centrifuged at 
1000 g for 15 min. The EtOH was poured out and the plasmid pellet was air-dried for 
about 10 min. Finally the plasmid was dissolved with 25 |xL distilled H2O and stored 
a t 4 � C 
3.8.4 Plasmid sequencing 
The sequencing analyses were performed with the ABI PRISMTM BigDye™ 
Terminator Cycling Sequencing Ready Reaction Kit (Applied Biosystems, Foster 
City, CA). Firstly, the concentration of the plasmid was assessed through agarose gel 
electrophoresis photometry. The cycle sequencing reaction was prepared as the 
following. Each reaction contained 0.8 ^L Big Dye, 0.5 |iL Ml3 Forward or Reverse 
primer with a concentration of 1.6 |iM, 2.7 jiL ddHiO and 0.05-0.2 ^g plasmid DNA 
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(the volume of H2O and plasmid DNA could be adjusted depending on the 
concentration of plasmid DNA). The thermal cycling reaction was carried out in an 
MJ DNA Engine Dyad® Thermal Cycler. The cycle sequencing reaction started 
with an initial denature step of 96 °C for 1 min and a following 30 thermal cycles (96 
�C for 15 s, 52 °C for 15 s and 6 0 � C for 2 min ). 
The sequencing reaction products were purified with EtOH precipitation 
supplemented with NaOAc and washed with 70% EtOH. In detail, a master mix was 
prepared as 3|il 3M NaOAc (pH5.2), 62.5^1 95% EtOH and 14.5^1 ddHzO for each 
80|il. Every 20ij1 master mix solution was aliquoted to each reaction tube and 
incubated at room temperature for 15 min. DNA was then precipitated by 
centriftigation at 2500g/30min (for 96-well plate) or at 20,000g /15min (for PCR 
tube). Supernatant was discarded and 80)LI1 of 70% EtOH was added into the tubes. 
The pellets were washed by centrifUgation at 2500g/10 min (for 96-well plate) or at 
20,000g/5min (for PCR tube). After discarding the supernatant, the pellets were 
allowed to air dry to remove all residue EtOH. 
The purified products were resuspended with 12 \iL Hi Di丁m formamide 
(Applied Biosystems) and were transferred to optical 96-well reaction plate (Perkin-
Elmer Life Sciences, Wellesley, MA) for sequence analysis by ABI 3100 Genetic 
Analyzer(Applied Biosystems). Sequencing data were extracted by the software 
Sequence Analysis. 
3.9 Homozygous deletion detection 
In order to investigate whether the homozygous deletions in gene ADAMTS8 were 
present the cell lines concerned, genomic multiplex PCR were performed in the both 
border regions of intron 1. In detail, reverse primer ADAMTSSIntlR in the 
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beginning of intron 1 and forward primer ADAMTS8F located at exonl were 
combined for exonl analysis. Forward primer ADAMTSSIntlF at the end of intron 1 
and reverse primer ADAMTS8R located at exon2 were combined for exon2 analysis. 
A 156 bp genomic DNA within the house keeping gene GAPDH was used as internal 
standard and was also amplified in the same reaction tube. The PCR reaction mixture 
was set as follows: 50 ng of genomic DNA of each sample was added in a final 
volume of 12.5 |LIL of PCR mixture, which also contained 1.25 |LIL lOX PCR buffer H, 
25 nMol MgCh, 2.5 nMol of each dNTPs (dATP, dCTP, dGTP and dTTP), 5 pMol 
of F/R primer for deletion screening, 2.5 pMol of GAPDH primer, and 0.3125U 
AmpliTaq gold. The PCR was carried out in an MJ DNA Engine Dyad® Thermal 
Cycler. The program started with an initial denature step at 95°C for 10 min to 
activate the polymerase enzyme, followed by 32 cycles (94°C for 30s, 55°C for 30s 
and 72°C for 30s) of amplification, with a final extension step at 72°C for 10 min. 
All of the PCR products were analyzed on 1.8% agarose gel containing EtBr and 
visualized under UV light. The presence of homozygous deletion was determined by 
the total loss of PCR products with the detection primer sets when the internal 
standard PCR products were present. 
3.10 Construction of expression plasmids 
3.10.1 The strategy of full length cDNA cloning 
The ADAMTS8 coding region was 2673 bp and it was divided into three fragments 
for PCR cloning. The primer combinations for the PCR amplification of the three 
fragments are ADAMTS8Fclonla/ADAMTS8Rl, ADAMTS8F/ADAMTS8Rclonl 
and ADAMTS8Fclon2/ADAMTS8Rclon2. The first two PCR amplification 
fragments were merged by graft PCR. In graft PCR, the overlapping regions of the 
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two DNA fragments would prime each other and extend using each other as the 
template. The resulting products were cloned in the Zero Blunt TOPO PGR cloning 
vector (Invitrogen, Carlsbad, CA, USA). The third PGR amplified fragment was also 
cloned into the Zero Blunt TOPO PGR cloning vector. The insert containing the first 
two fragments was then merged with the third fragment using the Bglll restriction 
site. The full length cDNA was finally subcloned to pcDNA3.1(+)(Invitrogen, 
Carlsbad, CA, USA) expression vector. The procedures were illustrated in the Fig. 3-
1. 
The full length cDNAs of HNT and BARX2 genes are 1062 bp and 840 bp 
separately. The full length cDNAs were amplified directly from human normal 
larynx RNA reverse transcription reaction product (prepared as described in 3.5) 
using Fclon/Rclon primer combinations. The PCR products were purified and cloned 
into Zero Blunt TOPO PCR cloning vector for sequence verification. The sequence 
verified HNT full length cDNA clone was restriction digested with Xhol and Hindlll 
and subcloned into pcDNA3.1 empty vectors. The sequence verified BARX2 full 
length cDNA clone was digested with EcoRI and subcloned into pcDNAS.l empty 
vectors, and the cloning was subsequently checked by restriction digestion with Nhel 
and KpnI. 
The primers were designed based on the sequence of the mRNA in the 
Entrez database with the accession number NM007013 (ADAMTS8), NMO16522 
(HNT), and NM003658 (BARX2) separately. 
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Fig. 3-1. ADAMTS8 full length cDNA cloning strategy and the major restriction 
sites in the expression vector around the insert. The ADAMTS8 coding region was 
indicated with solid line and the arrows accompanied indicated the orientation of the 
sense transcript. In the final expression vector construct, the original sources of 
different DNA fragments were marked with specific shape of lines. 
3.10.2 Obtaining of full length covered cDNA by cloning PCR 
The details for the PCR reactions were conducted with AccuPrime^^ Taq DNA 
Polymerase High Fidelity (Invitrogen, Carlsbad, CA, USA). For each PCR reaction, 
2.5 fxL lOX AccuPrimeTM PCR Buffer I， 5 pM forward and reverse primer 
separately, 0.1 i^L AccuPrime™ Taq DNA Polymerase High Fidelity, 0.125 i^g RT 
product and appropriate volume of H2O for a final volume of 25 |xL. The PCR was 
carried out in an MJ DNA Engine Dyad® Thermal Cycler. The PCR program started 
with an initial denature step at 94�C for 2 min, followed by 32 cycles (94°C for 30s, 
55°C for 30s and 68°C for 60-120s depending on the expected product size with the 
rate of 60s per kb) of amplification, with a final extension step at 68°C for 30 min. 
All of the PCR products were used for gel electrophoresis detection. The PCR bands 
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were stained with EtBr and visualized under UV light. The expected PCR products 
were excised under UV (long wave) and isolated out. The DNA fragments contained 
in the agarose gel slices were purified using SpinX column by centrifligation at 
20,000g for I min. 
The graft PCR was performed with similar conditions except that appropriate 
volumes of purified first round PCR products were used as the DNA substrate. The 
dNTPs (dATP, dCTP, dGTP and dTTP) were also supplemented with the final 
concentration of 0.2 mM for each. 
3.10.3 Ligation and transformation 
The PCR products were cloned into Zero Blunt TOPO PCR cloning vector for 
sequencing and subcloning. The principle of the kit and the procedures of ligation 
and transformation reactions are similar to TOPO TA cloning kit as described in 
3.9.2. The difference is that the vector harbors kanamycin and zeocin resistance 
genes and the transformants were usually selected on kanamycin contained LB agar 
plates. 
3.10.4 Mini preparation of plasmid in Eppendorf tubes 
For each agar plate, about 5 colonies were analyzed. Single bacteria colonies were 
inoculated in the 10 mL Falcon tubes containing 1.5 mL LB medium with kanamycin 
antibiotics (0.05 )ig/mL) and cultured at 37 °C overnight with a shaking speed of 250 
rpm. 
The plasmid mini preparations in tubes were performed as following. Firstly, 
about 1.3 mL cultured medium was transferred into a 2 mL eppendorf tube and was 
spun at 7000 g for 1 min. The supernatant was removed by aspiration. Then the 
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bacteria were lysed by alkaline lysis solution as the following: the bacteria pellet 
was resuspended in 150 fxL Solution I and incubated at room temperature for 10 min 
following vortexing. The bacteria were then lysed by adding 300 i^L freshly prepared 
Solution II，with gentle mixing until the mixture became clear (3-5 min). The lysate 
was immediately neutralized with 225 i^L ice cold Solution III and incubated at room 
temperature for 5 min. The mixture was then subject to centrifugation for 10 min at 
20,000g. After centrifugation, about 500 |xL clear suspension were take out carefully 
to a new tube and 300 fxL isopropanol was added. After incubated for 15 min at room 
temperature, the plasmid was precipitated by centrifugation at 20,000g for 10 min at 
room temperature and washed with 700 |LIL of 70% EtOH. Finally, the pellet was air-
dried and dissolved in 40 fiL distilled H2O. The plasmid was stored at 4 °C for 
further use. 
3.10.5 Verification of correct inserts in the plasmid 
The presence of insert was checked by digestion of the plasmid with specific 
restriction endonuclease. The restriction reactions were performed in a total 10 |xL 
volume composed of IX reaction buffer, IX BSA if needed, 0 . 2 � 1 |Lig of plasmid 
DNA and distilled H2O. All of the digested products were analyzed on agarose gel 
containing EtBr and visualized under UV. If the expected restriction products existed, 
the inserts were sequenced as described in 3.9.4. Only when the proper reading frame 
was obtained without any missence mutation, the plasmid could be used for 
subsequent subcloning reaction. 
3.10.6 Subcloning 
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Subcloning reactions were performed according to the strategies described above. 
For the subcloning of BARX2, both the plasmid containing full length BARX2 cDNA 
and the plasmid of pcDNA 3.1(+) empty vector were digested with EcoRL The 
digestion product of pcDNA3.1(+) (linearized vector) was dephosphorylated using 
alkaline phosphatase, shrimp (SAP, Roche). In details, the activity of EcoRI was 
firstly inactivated at 65 °C for 20 min. Then 1.2 i^L lOX dephosphorylation buffer 
and 1 iliL SAP was added. After incubation for 10 min at 37 °C, SAP was inactivated 
at 6 5 � C for 15 min. The dephosphorylated linearized empty vector was kept at -20 
� C for use. For the BARX2 cDNA contained TOPO vector digestion product, the total 
DNA was electrophoresed on agarose gel and the desired insert was excised under 
UV. The DNA in the gel slice was purified using QIAEX II gel extraction kit. In 
brief, 500 |LIL of Buffer QXl and 8 i^L resuspended QIAEX II was added to the tube 
containing the gel slices. The mixture was incubated at 5 5 � C for 10 min with 
vortexing every 2 min. Then the mixture was centrifuged at 20,000g /30 sec and the 
supernatant was carefully removed. The pellet was washed once with 500 [iL Buffer 
QX I and twice with 500 ^L Buffer PE. The pellet was then air-dried and the DNA 
was eluted with 10 i^L TE buffer (10 mM Tris-Cl，PH 8.5). The purified insert DNA 
fragment was ligated into the linearized pcDNA 3.1 vector using T4 DNA Ligase 
(Roche). The reaction contained 1 i^L lOX ligation buffer, 1 jiL of linearized pcDNA 
3.1(+) vector and 3 times of insert DNA(molar ratio), 1 |iL T4 DNA ligase and 
appropriate H2O to a final volume of 10 |LIL. The ligation was carried out at 4 � C 
overnight. The ligation product was transformed into DH5 competent cells 
at the next day as described in 3.9.2. Verification of the correct insert ligation was 
performed as described above. For the cloning of ADAMTSS and HNT, similar 
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procedures were performed but the dephosphorylation reaction could be omitted if 
directional subcloning strategies were applied. 
3.10.7 Bacteria storage 
The transformant bacteria colony was kept at - 80 °C for long term storage. The 
fresh bacteria in the log phase were mixed well with one third volume of autoclaved 
glycerol for storage. 
3.11 Colony formation assays (CFA) 
3.11.1 Midiprep of the transfection grade plasmid 
Midi preparation of the transfection grade plasmid DNA was performed using the 
EndoFree® Plasmid Maxi Kits (QIAGEN, Germany) as the manufacturer's protocol. 
For bacteria culture, 15 |LIL of the kept bacteria were inoculated in 1 mL LB with 
antibiotics and were cultured at 37 °C for approximate 8 hrs with vigorous shaking. 
Then 50 |LIL of the starter culture was transferred into 50 mL LB medium with 
antibiotics. The bacteria were cultured overnight and harvested by centrifugation at 
6000 g/15 min at 4 The cell pellet was resuspended with 4 mL Buffer PI 
supplemented with RNase A (100 ^ig/mL). Then the cells were lysed by 4 mL Buffer 
P2. After an incubation of 5 min, the cell lysate was neutralized with 4 mL chilled 
Buffer P3. Then the cell debris were cleared by filtration of the mixture using 
QIAfilter Midi Cartridges and the cleared solution was mixed with 1 mL Buffer ER. 
After incubation on ice for 30 min, the mixture was applied to a QIAGEN-tip 100 
which had been equilibrated with 4 mL Buffer QBT. The plasmid DNA in the lysate 
banded to the resin as the liquid flow down through the column by gravity. The 
column was washed twice with 10 mL Buffer QC each time and the plasmid DNA 
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was eluted with 5 mL Buffer QF. Finally, the plasmid was precipitated by adding 3.5 
mL of isopropanol and centrifuged at 20000g for 30 min at 4 °C. After discarding the 
supernatant, the pellet was washed with 2 mL 70% EtOH. The air-dried pellet was 
dissolved with 200 |LIL sterile distilled H2O. The concentrations of the plasmid were 
estimated by gel electrophoresis and determined by spectrophotometer. 
3.11.2 Transfection 
The ectopic expression of the interested genes in the eukaryotic cells was achieved 
by transfecting the pcDNA3.1 recombinant vector into the cells using FuGENE 6 
Reagent (Roche Applied Science, Germany). FuGENE 6 transfection reagent is 
composed of lipids and other components. The cationic lipids could react 
spontaneously with plasmid DNA to form a unilamellar shell which can fuse with 
cell membranes and take the DNA into cells. The formation of DNA-lipid complexes 
is due to ionic interactions between the head group of the lipid carrying a strong 
positive charge and phosphate groups on the DNA with negative charge. 
A day before transfection, the cells were subcultured to the 12-well-plate. The 
medium was removed and the adhering cell monolayer was washed with PBS. Then 
the cells were detached by trypsin with incubation at 37 °C for 5 min. The trypsin 
was neutralized by complete growth medium containing FBS. Subsequently, the cell 
suspension was homogenized and the cell density was determined using a 
hemacytometer. Then the cells were diluted to 0.5�2.0 * 10^  with the complete 
medium. Finally, the cells were distributed into the specific wells of the 12-well-
plate and were maintained in the 37 °C incubator. 
Once the 50-80% of cell confluence was reached, the cells were transfected 
with the empty vector or the expression vector (0.5^g each). Firstly, 47.6 serum 
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free RPMI medium and 2.4 ^L Fugene reagents were aliquoted to a sterile Eppendorf 
tube sequentially. After 5-10 min incubation at room temperature, 0.8 jug plasmid 
DNA was added into the tube and mixing. The mixture was incubated at room 
temperature for 30 min to make the transfection complex. Meanwhile, the medium in 
the 12-well-plate was changed. Finally, the entire transfection complex was drop-
wised into the designated wells. After complete mixing, the cells were returned into 
the incubator. 
3.11.3 Selection of the transfected cells with G418 
Selective antibiotic G418 is an aminoglycoside drug and could block protein 
synthesis in mammalian cells by interfering with ribosomal function. G418 is toxic to 
normal cells and is used as a selective agent in molecular genetics experiments. 
However, expression of the bacterial aminoglycoside phosphotransferase gene 
(derived from Tn5) in mammalian cells results in detoxification of G418. The 
pcDNA3.1 vectors contain the neomycin resistance gene and introduction of these 
vectors into cells confers resistance to G418. In CFA, G418 is used for isolation of 
the transformant from a background of nontransfected cells. 
Firstly, the selective medium was prepared with complete RPMI medium 
supplemented with G418 (Calbiochem, Germany) at a concentration of 400 |xg/mL. 
The drug concentration needs to be optimized for different cell lines. After 
transfection for about 48 hrs, the cells were washed with PBS and treated with 
trypsin as previously. After the cells were detached, the trypsin was neutralized with 
selection medium. The cell mixture was diluted with optimization and distributed to 
designated wells of 6-well-plate. 
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In the following 2 to 3 weeks, the selective medium was changed every 2 to 3 
days until the appropriate colony formed. 
3.11.4 Colony staining 
The surviving colonies were stained with GENTIAN Violet (ICM Pharma, 
Singarpore). Firstly, the medium was discarded and the cells were washed with PBS. 
The cells were then fixed with methanol for 10 min followed by staining with 
GENTIAN Violet for 10 min. Finally the cell monolayer was washed with water. 
The results were photographed and the colonies in each well were counted. 
3.12 Statistical analysis 
The results are expressed as values of mean士SE. Statistical analysis was carried out 
with Student's t-test by using the software GraphPad Prism 3.02 (Graphpad Software, 
San Diego, CA), p<0.05 was considered as statistically significant difference. 
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Chapter Four: Results 
4.1 Narrow down the candidate genes for further study 
4.1.1 Define the study chromosome region 
Previously a high-resolution 1-Mb array-CGH experiment was performed in a 
panel of NPC and ESCC cell lines. In the experiment, 3040 BACs were used for 
screen and several hotspots were found to illustrate frequent deletions or 
amplifications. The regions with frequent deletions in tumors are believed to harbor 
critical novel TSGs. In my project, the study chromosome region was defined at a 
proximate six Mb area in human chromosome 11 restricted by BACs bA168K9 
(126,420,648 to 126,568,009) and bA419F8 (132,215,897 to 132,391,418). These 
two clones and other three BACs all showed frequent deletions in the array-CGH 
tests. The other three BACs located in the region include bA264E20 (127,930,601 to 
128, 090,813), pAC1064E20 (130,960,053 to 131,065,134) and bA340L13 
(130,972,996 to 131,149,195). An overview of the study region in human 
chromosome 11 was displayed in Fig. 4-1(A) and it demonstrated that the minimal 
deletion region (MDR) was defined at llq24.2 to q25. This chromosome region was 
set as the target for intensive search to identify novel TSGs with the cancer models 
NPC and ESCC. 
4.1.2 Database search of all candidate genes 
By searching the human genome database Entrez ‘, Ensembl^ and Human 
Genome Browser Gateway^，a total of 34 genes were retrieved from the study 
1. http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi 
2 . http://www.ensembl.org/Homo—sapiens/mdex.html 
3 . http://genome.ucsc.edu/cgi-bin^gGateway 
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chromosome region accompanied with exons and mRNA information. The gene 
identities and their relative positions were shown in Fig. 4-1(B). 
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Fig. 4-1. The studied chromosome region and the 34 candidate genes residing in 
the region. 
(A). An overview of the studied region {boxed) in human chromosome 11 and 
illustration of the region in Ensembl database. The minimal deletion region (MDR) 
was defined by five BAC clones. The corresponding sequence of the five clones 
showed frequent deletions detected by the high-resolution 1-Mb array-CGH test in a 
panel of NPC and ESCC cell lines. These clones are bA168K9, bA264E20, 
pAC1064E20, bA340L13 and bA419F8. In the below panel, the candidate genes 
were shown in the "Ensembl Genes". More information (e.g. the exon-intron 
organization and m-RNA sequence) about the genes was obtained by accessing the 
hyperlinked websites of the genes. 
(B). Illustration of the relative arrangement of the 34 candidate genes in the study 
region. The genes of the below panel included all the genes with coding stands on the 
reverse complemented strand of genomic DNA and the direction of the arrows 
pointed to the left. On the contrary, the genes of the upper panel use another DNA 
stand as the coding strand. Some genes combinations (LOC387821 and FLIl, 
MGC35558 and KCNJ5, underlined in the figure) were shown to have the genomic 
localization overlapped but with the coding strands on different DNA strands. 
4.1.3 Transcriptional expression analysis of the candidate genes 
In order to search for genes involved in NPC and ESCC tumorigenesis, the 
mRNA expression of all the 34 genes were examined by semiquantitative RT-PCR in 
a panel of NPC and ESCC cell lines with larynx, trachea, esophagus and testis as 
normal tissue controls. Six NPC cell lines, C666-1, CNEl, CNE2, HKl, HNEl and 
HONEl, and three ESCC cell lines, EC 18, EC 109 and KYSE410, were used in the 
expression profile analysis. Two immortalized normal esophageal epithelial cell lines 
NEl and NE3 were also included. The PCR results were shown in Fig. 4-2(A). Seven 
genes could not obtain clear expected product bands and they were amplified again 
with 5% (v/v) DMSO supplemented in the master mix, with two genes {LOC219797 
and FLJ45436) obtaining better amplification. The results were shown in Fig. 4-2(B). 
But the other five genes amplification results had no obvious improvement (data not 
shown) and the PCR reactions were not performed in the three ESCC cell lines. 
Two genes, LOC387823 and FLJ45436, showed clear extra PCR product 
bands with unexpected sizes. The extra bands were sliced and subject to direct 
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sequencing with the RT-PCR primers after purification. The sequencing results were 
summarized in Table 4-1. 
4.1.4 Selection of the genes with tumor specific expression downregulation for 
further intensive study 
The bioinformatics searching was performed on the genes with tumor specific 
expression downregulation to retrieve the previous discoveries from the gene 
databases and published papers. The information retrieved was summarized in the 
Table 4-2. 
In this process, it was found that gene ST14, which showed downregulation in 
one of the tested ESCC cell lines, had been intensively studied in multiple tumor 
types and was characterized as a putative TSG. Another gene LOC387821 was a 
predicted gene and its full length sequences of mRNA and peptide were not fixed yet. 
Therefore, these two genes were excluded for further studies. 
The "class 11" TSGs, the searching targets of this study, are frequently 
inactivated by aberrant promoter methylation in tumors. To find out whether 
promoter CpG island methylation was associated with the gene expression 
downregulation identified above, the transcription reactivation studies of these genes 
were performed by demethylation treatment. Some of the cell lines with candidate 
genes expression downregulation were subject to demethylation treatment with 5-
aza-2'-deoxycytidine alone or combined together with trichostatin A. The mRNA 
expression levels after treatment were examined by semiquantitative RT-PCR. The 
results were shown in Fig. 4-2(C) and summarized in Table 4-2. The results revealed 
that transcriptional expression upregulations were found in five of five cell lines for 
ADAMTS8, three of five cell lines for HNT, one of one cell line for ADAMTS15, one 
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of one cell line for BARX2 and two of two cell lines for FLIL These results indicated 
that aberrant promoter methylation might be involved in the expression 
downregulation of all the five genes. Therefore, these genes were subject to further 
characterization to identify candidate TSGs. 
Table 4-1. The sequencing results of extra unexpected RT-PCR products 
B l a s t ~ 






AAACTCCCAAAGC GGCCAATGACCAAATGGAAATCCTCGACAGCTTGATCAGAGAG Homo 
LOC AGGGACTTTCAGG ATGCGGCAGATGGGCCAGCCCTGTGATGCTTACCAGAAAAGGC sapiens 
3878 CCCACATGCACTT TTCTTCAGCTCCAAGAGCAAATGCGAGCCCTTTATAAAGCCATC DSP 
23 AGCCTCCTCTTCCC AGTGTCCCTCGAGTCCGCAGGGCCAGCTCCAAGGGTGGTGGAG transcript 














GACCTCTGGTGAT GACTGTGGTCTGCCAATGAGACATCAGAGGCAGCAGTTCCTTG No 
FLJ CCGCCCACCTCGG AATATTTCCCCTGCTCTGGACCCTGAGGGAGGGAACTGATACC homolo-
4543 CCTCCCAAAGTGC AGAGGTCTTTTCTATCTTTAGTATCTATACCTACATGTCTTCCTC gue 
6 TGGAATTACAGGC TATTGCACAGGGATGCTCTCTCTGCCTTCTCAGTGCTTACATCT transcript 
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Fig. 4-2. Transcriptional expression profile of the 34 candidate genes in a panel 
of NPC and ESCC cell lines with normal controls and selection of the 
downregulated genes for further study. 
(A).RT-PCR results of all 34 candidate genes in a panel of NPC and ESCC cell lines 
with normal controls. The six NPC tumor cell lines were C666-1, CNEl, CNE2， 
HKl, HNEl and HONEl and the three ESCC cell lines were EC 18, EC 109 and 
KYSE410. Four related human normal tissues (larynx, trachea, esophagus and testis) 
and two immortalized normal cell lines developed from esophageal epithelium (NEl 
and NE3) were used as accompanied normal controls. Left, the cell lines and normal 
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tissues {underlined) used. Top, the genes loci checked. GAPDH served as the 
positive control and control for RNA integrity examination. For OPCML, the suffix 
notation VI and V2 used different primer combinations separately for the 
amplification of different transcription variants. The gene loci boxed indicated that 
the transcription was downregulated in at least one tumor cell lines compared to 
corresponding normal control. The gene loci italicized concomitant with “-’’ as the 
prefix indicated that these genes were amplified again with 5% (v/v) DMSO in the 
master mix due to lack of clear expected PCR product bands. M, the lane of DNA 
ladder markers (lOObp, the same in the latter in this thesis). Two genes, LOC387823 
and FLJ45436, showed clear extra PCR product bands with the unexpected size as 
the white arrows indicated in figure A and B. 
(B). Improved amplification of L0C219797 and FLJ45436 when supplemented with 
5% DMSO in the PCR maste mix. The expected PCR product bands clearly appeared 
in LOC219797. For FLJ45436, the expected 246 bp product also appeared in the 
lower band. 
(C). Transcription reactivation of the downregulated genes through demethylation 
treatment. Left, the genes subject to the study. Top, the cell lines before and after 
treatment with demethylation drugs (A: treated with 5-aza-2'-deoxycytidine alone; 
A+T: treated with 5-aza-2‘-deoxycytidine combined together with trichostatin A). 
Normal tissue larynx was used as the positive control and H2O as the negative 
controls. The results indicated that most of transcription downregulation expression 
cases could be upregulated by demethylation treatment. 
4.2 Further characterization oiADAMTSS 
4.2.1 Tissue transcriptional expression panel 
The transcriptional expression profile of ADAMTS8 in human adult and fetal 
tissues was examined by semiquantitative RT-PCR as shown in Fig.4-3(B). 
ADAMTS8 was found strongly expressed in most of human adult normal tissues 
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including larynx, trachea and esophagus. A relative lower level of ADAMTS8 
expression was observed in the adult lymph node and bone marrow. 
4.2.2 Semiquantitative RT-PCR results in tumor cell lines 
The mRNA expression levels of ADAMTS8 were studied in multiple tumor 
cell lines. The tumor types included NPC, ESCC, HCC, gastric cancer, breast cancer, 
cervical cancer, colon cancer, lung cancer, RCC and prostate cancer. The 
immortalized normal epithelial cell lines NP69, NEl, NE3, Het-IA, HMEC, HMEpC, 
HEK293 and RHEK-1 were used as normal controls for related cancer. The results 
were shown in Fig. 4-3 (C). ADAMTS8 showed high frequency of expression 
downregulation (more than 60%) in all types of cancer cell lines. Notably, 
ADAMTS8 was totally silenced in all six examined NPC cell lines, but showed 
moderate expression in normal immortalized nasopharynx epithelial cell line NP69, 
indicating its especially important role in the pathogenesis of NPC. These results 
were summarized in Table 4-3 (a). 
4.2.3 Promoter CpG island identification and promoter methylation study 
The 5' promoter sequence of ADAMTS8 was retrieved from Human Genome 
Browser Gateway database. Analysis of this region sequence by online CpG Island 
Searcher tool! identified the presence of typical CpG island as shown in Fig. 4-3 (A). 
It showed that the CpG island covers the whole exon 1 and has a high CpG site 
density, with a G/C nucleotide percentage of 66.8% and an observed to expected 
CpG ratio of 0.779. 
1. http://www.uscnorris.com/cpgislands2/cpg.aspx 
70 
Table 4-3 Summary of ADAMTS8 expression downregulation and promoter 
methylation in tumor samples 
(a) Results in tumor cell lines 
Samples(Tumor RT-PCR Result MSP Result 
cell lines) (Frequency of 
Frequency of totally Frequency of downregulation methylation) 
silenced (including silenced cell lines) 
NPC 6/6 (100%) 6/6 (100%) 6/6(100%) 
ESCC 4/17 (24%) 15/17(88%) 2/17(12%) 
HCC 4/13(31%) 11/13(85%) 1/13(8%) 
Gastric Cancer 5/11 (45%) 7/11 (64%) 6/11 (55%) 
Breast Cancer 5/9 (56%) 7/9 (78%) 2/9 (22%) 
Cervical Cancer 1/4 (25%) 3/4 (75%) 1/4 (25%) 
Lung Cancer 1/5 (20%) 5/5 (100%) 1/5 (20%) 
Colon Cancer 3/4 (75%) 3/4 (75%) 3/4 (75%) 
RCC 2/7 (29%) 5/7 (71%) 2/7 (28%) 
Prostate Cancer 0/2 (0) 2/2 (100%) 0/2 (0) 
(b) Results in clinical samples 
Samples Frequency of methylation % (by MSP) 
Primary carcinomas NPC 6/49 (12%) 
ESCC 0/24 
Breast Cancer 0/18 
Colon Cancer 0/18 
Gastric Cancer 4/69 (6%) 
Nasopharyngitis 0/7 
The promoter methylation statuses in the cell lines were examined by MSP 
using the primer combinations ml/m2 or m3/m4 as shown in Fig. 4-3(A). The MSP 
results were shown in Fig. 4-3 (C). The results revealed that the methylation statuses 
were closely correlated with the statuses of transcriptional expression. In detail, the 
presence of expression always accompanied with the presence of unmethylated 
alleles and the expression was totally silenced in all of the cell lines with the 
presence of methylated alleles accompanied the absence of unmethylated alleles. 
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Meanwhile, the results revealed that the percentage of promoter methylation varied 
greatly among different tumor types, with 100% of cell lines methylated in NPC, but 
only 8% of cases methylated in HCC. These results indicated that different major 
mechanisms were involved to silence ADAMTS8 in different tumor types. Moreover, 
all eight examined immortalized normal epithelial cell lines did not show any 
promoter methylation, indicating the detected methylation was tumor specific. The 
frequencies of presence of methylation were also summarized in Table 4-3 (a). 
4.2.4 Transcription reactivation by demethylation treatment 
To further elucidate whether the promoter methylation was responsible for 
the consequences of ADAMTS8 downregulation, several cell lines with ADAMTS8 
downregulation were subject to demethylation treatment, with 5-aza-2'-
deoxycytidine alone or combined together with trichostatin A. After the treatment, 
the reactivation of gene expression was examined by RT-PCR and the effect of 
demethylation in the seven cell lines with methylation was examined by MSP. The 
results were shown in Fig. 4-3 (D). Obvious expression upregulation was observed in 
all tested cell lines. The demethylation effects were also demonstrated by MSP in 
most cell lines. That is, the results showed decreased methylation specific PCR 
products accompanied with increased unmethylation specific products. These results 
confirmed that ADAMTS8 promoter methylation was correlated with its 
transcriptional expression downregulation. 
4.2.5 High resolution promoter methylation analysis by BGS 
To examine ADAMTS8 methylation in more detail, the methylation statuses 
of the entire 63 CpG sites in a 519 bp promoter region were examined by BGS. The 
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BGS region was shown in Fig. 4-3(A). The results illustrated in Fig. 4-3 (D) 
confirmed the MSP results. In detail, heavily methylated alleles were observed in the 
untreated tumor cell lines which showed methylation specific PCR products in MSP 
reaction, and these cell lines are C666-1, HONEl, CNE2, KYSE150, KatoIII, CaSki, 
MB231 and HCT116BV. Additionally, the unmethylated alleles appeared after 
demethylation treatment in the cell lines CNE2, C666-1, MB231 and HCT116 which 
were consistent with MSP results. In the genetic demethylation cell line DKO with 
double genetic knock out of DNMTl and DNMT3B, the methylation was rarely 
detected which was commendably correlated with the expression upregulation 
observed. 
4.2.6 Detection of homozygous deletion 
To further investigate whether genomic deletion events were involved in the 
expression silencing of ADAMTS8, the multiplex genomic PCR was performed with 
simultaneous amplification of part GAPDH gene as internal control. The two 
genomic regions at both edges of ADAMTS8 intron 1 were screened for the presence 
of homozygous deletions using primer combinations F/IntlR and IntlF/R separately 
as shown in Fig. 4-3 (A). The DNA extracted from normal adult Peripheral Blood 
Mononuclear Cells (PBMC) was used as normal control. The multiplex PCR results 
were shown in Fig. 4-3 (F). The results revealed that the ADAMTS8 deletion 
detection region and the control GAPDH region were efficiently amplified 
simultaneously. No homozygous deletion events were observed in the two screened 
genomic regions in the examined cell lines. 
73 
4.2.7 Analysis oiADAMTSS promoter methylation in clinical samples 
To examine whether the ADAMTS8 promoter methylation detected in tumor 
cell lines was also present in clinical primary tumors, the methylation statuses were 
checked in the bisulfite DNA from clinical primary tumor samples. The tumor types 
include NPC, ESCC, breast cancer, colon cancer and gastric cancer. Low frequency 
of ADAMTS8 promoter methylation, 12% and 6% separately, was detected in NPC 
and gastric cancer primary samples. The results were summarized in Table 4-3 (b) 
and the representative PCR results were shown in Fig. 4-3 (G). 
To further elucidate whether the presence of methylation detected in tumor 
samples was tumor specific, seven biopsy nasopharyngeal tissues from 
nasopharyngitis patients were also subject to ADAMTS8 methylation analysis. As 
shown in Fig. 4-3(G)，no promoter methylation was observed in these nonmalignant 
clinical samples, indicating the methylation was tumor specific. 
4.2.8 ADAMTS8 full length cDNA cloning 
The Ml length cDNA of ADAMTS8 was cloned in the pcDNA3.1(+) 
expression vector as described in chapter three. The Flag sequence (with the 
nucleotide sequence GATTACAAGGATGACGACGATAAG) coding the eight 
amino acids peptide with the sequence DYKDDDDK was tagged immediately after 
ATG, and the consensus Kozak sequence GCCACC was added before ATG. The 
major restriction sites and their relative positions around the insert in the 
pcDNA3.1 {+)IY\digADAMTS8 expression vector were illustrated in illustrated Fig. 3-
1. The presence of the right insert was examined by restriction digestion with Hindlll 
and the restriction map was shown in Fig. 4-3 (H). Since the full length ADAMTS8 
cDNA contained insert was ligated to the pcDNA3.1 (+) empty vector by a 
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bidirectional cloning strategy, sense and antisense ADAMTSS expression vector 
could be obtained. Accordingly, the DNA restriction fragment after Hindlll digestion 
would be 1900 bp or 1050 bp separately. The expected different restriction fragments 
appeared in clone 1 and 2 respectively. The in frame insertion of ADAMTSS full 
length cDNA in clone 1 was verified by sequencing. 
4.2.9 Colony formation assay 
To evaluate the role of ADAMTSS as a TSG in carcinomas, the inhibitory 
effects of ectopic ADAMTSS expression on tumor cells were examined. The cloned 
expression vector with full length ADAMTSS gene was transfected into the NPC cell 
line HONEl and a colon carcinoma cell line HCT116 which previously showed 
virtually no ADAMTSS expression. The empty pcDNA3.1(+) vector was also 
transfected as the negative control. The colony formation efficiency of transfected 
cells was evaluated by monolayer culture. As shown in Fig. 4-3 (I), a significant 
reduction of colony formation efficiencies was observed in cells transfected with 
pcDNA3.1 {+)!ADAMTSS. The colony number decreased to 47% and 19% separately 
in cell line HONEl and HCT116, compared to the empty vector control. Thus, 
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Fig.4-3. Characterization of tumor suppressor candidate ADAMTS8, 
(A). Schematic structure of ADAMTS8 promoter CpG island. Locations of the core 
promoter, exons 1 and 2 {filled rectangles) and the CpG sites in the CGI {short 
vertical lines). The start site of coding region (starts with ATG) was indicated by a 
curved arrow. The CGI, MSP (ml/m2 or m3/m4), BGS, RT-PCR (F/R) and 
multiplex genomic PCR (F/IntlR and IntlF/R) regions analyzed were indicated. The 
length of line indicating intro 1 did not represent the actual length. 
(B). Broad expression of ADAMTS8 in human normal adult and fetal tissues as 
detected by semiquantitative RT-PCR, with GAPDH as a control. Sk.M, skeleton 
muscle; LN, lymph node. 
(C). Representative expression of ADAMTS8 by semiquantitative RT-PCR and 
promoter methylation analysis by MSP in various carcinoma cell lines. Immortalized 
normal epithelial cell lines NP69, NEl, NE3, Het-IA, HMEC, HMEpC, HEK293 
and RHEK-1 {boxed) were used as normal controls. M, methylated; U, unmethylated. 
The presence of methylated PCR product indicated the presence of promoter 
methylation. ADAMTS8 expression was frequently downregulated in all types of 
cancer cell lines. But the percentage of promoter methylation varied greatly among 
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different tumor types. In the case of NPC, 100% of cell lines showed ADAMTS8 
expression silencing and promoter methylation, indicating especially prevalent 
epigenetic silencing of ADAMTS8 in the process of NPC tumorigenesis and 
progression. Notably, none of the eight normal control cell lines showed methylation. 
The ADAMTS8 expression inactivation in colon tumor cell line HCT116 could be 
partially restored by genetic demethylation through double genetic knock out of 
DNMTl and DNMT3B (DKO) as indicated with white arrow. The results were 
summarized in Table 4-3. 
(D). Pharmacologic demethylation and upregulation of ADAMTS8 expression in 
tumor cell lines. Left, the reactivation of gene expression was checked by RT-PCR 
and the effect of demethylation was examined by MSP. Top, the cell lines before and 
after treatment with demethylation drugs (A: treated with 5-aza-2'- deoxycytidine 
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alone; A+T: treated with 5-aza-2 ‘ -deoxycytidine combined together with trichostatin 
A). ADAMTS8 expression was upregulated in all of the cell lines examined. 
(E). Representative high-resolution analysis of the methylation status of individual 
CpG sites in ADAMTS8 promoter by BGS. Left, multiple carcinoma untreated cell 
lines and cell lines with pharmacologic or genetic demethylation treatment; Top, the 
representative number of the specific CpG sites for each column and the locations of 
MSP primer {thick arrows); right, the corresponding MSP results and ADAMTS8 
expression statuses. For the BGS results, each row indicates a promoter DNA allele 
analyzed and each circle corresponds to a single CpG site. Methylated sites are 
indicated as filled dark circles while unmethylated sites as white ones. From the 
results, dense methylation was observed in the tumor cell lines with silenced 
ADAMTS8. After demethylation treatment, the unmethylated alleles appeared and 
the expression was reactivated. These results were closely correlated with the MSP 
results. 
(F). Detection of homozygous deletion by multiplex genomic PCR. Left, the deletion 
detection primer combinations; Top, the cell lines and normal human PBMC DNA 
control {underlined). Right, the 156 bp product {arrows indicated) amplified from 
GAPDH genomic region, acting as internal control. The expected products amplified 
from ADAMTS8 intron 1 border genomic regions were 301 bp and 349 bp separately. 
No homozygous deletion events were observed in the two screening ADAMTS8 
genomic regions in the examined cell lines. 
(G). Analysis of ADAMTS8 promoter methylation in clinical samples. Left panel, 
representative MSP (only M) results in NPC primary tumor samples. In a total, six 
samples were detected with ADAMTS8 promoter methylation with the sample 
number NPC63, NPC69, NPC76, NPC84, NPC85, NPC 106. Right panel, no 
ADAMTS8 promoter methylation was detected in seven nonmalignant biopsy 
nasopharyngeal tissues from nasopharyngitis patients. 
(H). The restriction map of ADAMTS8 full length cDNA constructs in the 
pcDNA3.1(+) expression vector. The full length cDNA contained plasmid was 
digested with Hindlll. The 1900 bp and 1050 bp digestion DNA fragments (white 
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arrows) appeared in clone 1 and 2 respectively for sense and antisense expression 
clone. 
(I). Growth inhibitory effects of ectopic ADAMTSS expression on tumor cells. Left, 
representative colony formation assays with monolayer culture to assess the TSG 
function ofADAMTSS. NPC cell line HONEl and colon carcinoma cell line HCTl 16 
were transfected with pcDNA3.1 (+) vector only or pcDNA3.1 (+)/ ADAMTSS. 
Compared to empty vector control, significant less tumor cells colonies formed when 
ADAMTSS was expressed. Right, quantitative analysis of colony numbers of HONEl 
and HCTl 16. The numbers of G418 resistant colonies in each vector transfected cell 
line were set to 100%. Values are mean 士 s.e. from three independent experiments. 
The P values were generated from student's t-test. 
4.3 Further characterization of HNT 
4.3.1 Tissue transcriptional expression panel 
The transcriptional expression panel of HNT in adult and fetal tissues was 
examined by RT-PCR and the results were shown in Fig. 4-4 (B). HNT is widely 
expressed in human adult and fetal tissues including epithelium though at different 
levels. High HNT expression levels were observed in adult larynx, trachea and 
esophagus. 
4.3.2 Semiquantitative RT-PCR results in tumor cell lines 
The mRNA expression levels of HNT were studied in multiple tumor cell 
lines with the immortalized normal epithelial cell lines as controls. The tumor types 
included NPC, ESCC, HCC, breast cancer, gastric cancer, cervical cancer, colon 
cancer, lung cancer, RCC and prostate cancer. The PCR results were shown in Fig. 
4-4 (C). HNT showed high expression levels in normal esophagus, breast, stomach, 
cervix, colon, lung and prostate tissues. An intermediate expression was also 
observed in normal liver and kidney. However, HNT expression was widely 
downregulated in all kinds of tumor cell lines, indicating that it might be involved in 
multiple cancer initiation and progression. These results were summarized in Table 
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4-4. In short, //AT was totally silenced in all of the NPC, ESCC and prostate cancer 
cell lines. Furthermore, HNT was also downregulated in more than 90% of tumor cell 
lines from gastric cancer, breast cancer, cervical cancer and colon cancer. 
Table 4-4 Summary of HNT expression downregulation and promoter 
methylation in tumor cell lines 
Samples RT-PCR Result MSP Result 
(Tumor cell (Frequency of 
lines) Frequency of totally Frequency of downregulation methylation) 
silenced (including silenced cell lines) 
NPC 6/6 (100%) 6/6 (100%) 5/6 (83%) 
ESCC 17/17(100%) 17/17(100%) 16/16(100%) 
HCC 42/12 (50%) 10/12(83%) 9/12(75%) 
Gastric Cancer 9/11 (82%) 10/11 (91%) 10/10 (100%) 
Breast Cancer 6/9 (67%) 9/9 (100%) 7/9 (78%) 
Cervical Cancer 3/4 (75%) 4/4 (100%) 4/4(100%) 
Lung Cancer 2/5 (40%) 3/5 (60%) 4/5 (80%) 
Colon Cancer 3/4(75%) 4/4(100%) 4/4(100%) 
RCC 2/7 (29%) 4/7 (57%) 3/7 (43%) 
Prostate Cancer 2/2 (100%) 2/2 (100%) 2/2 (100%) 
4.3.3 Promoter CpG island identification and promoter methylation study 
The 5' promoter sequence of HNT was retrieved from Human Genome 
Browser Gateway database. Typical CpG island was identified in this region 
sequence by CpG Island Searcher tool as shown in Fig. 4-4 (A). The CpG island lays 
over the whole exon 1 and has a high CpG site density, with a G/C nucleotide 
percentage of 64.3% and an observed to expected CpG ratio of 0.847. The promoter 
methylation statuses in the cell lines were examined by MSP using the primers 
shown in Fig. 4-4(A). The MSP results were shown in Fig. 4-4 (C). The results 
revealed that promoter methylation was present in nearly all of the tumor cell lines 
with HNT transcription downregulation. However, this methylation was absent in 
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most of immortalized cell lines from normal epitheliums, and only moderate 
methylation was observed in NP69. The frequencies of presence of methylation were 
summarized in Table 4-4. 
4.3.4 Transcription reactivation by demethylation treatment 
To study whether the consequences of HNT transcriptional expression 
downregulation was associated with promoter hypermethylation, several cell lines 
with transcription inactivation accompanied with promoter methylation were subject 
to demethylation treatment, 5-aza-2'-deoxycytidine alone or combined together with 
trichostatin A. The reactivation of gene expression was checked by RT-PCR and the 
effect of demethylation in five cell lines with expression restoration was examined 
by MSP as shown in Fig. 4-4 (D). The results indicated that in the examined 15 cell 
lines from different tumor types, only two cell lines, HKl and MB231, showed 
obvious expression upregulation. Four other cell lines, HONEl, C666-1，Hep3B and 
BT549, showed slight expression restoration. The demethylation effects in HKl were 
typical by obtaining a much weaker methylation specific PCR product band 
accompanied with a stronger unmethylation specific band. 
4.3.5 HNT full length cDNA cloning 
The full length cDNA of HNT was cloned in the pcDNA3.1(-) expression 
vector as described in chapter three. The Flag sequence coding the amino acids 
sequence DYKDDDDK was tagged immediately after ATG and the consensus 
Kozak sequence GCCACC was added before ATG. The major restriction sites and 
their relative positions around the insert in the pcDNA3.1(-)/Flag//AT expression 
vector were illustrated in right panel of Fig. 4-4(E-2). The presence of the right insert 
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was examined by restriction digestion with Nhel and Kpnl and the expected 
restriction fragment with the size 1130 bp appeared. The restriction map was shown 
in Fig. 4-4 (E-1). 
To further verify the obtained full length cDNA of HNT, the pcDNA3.1(-) 
/Flag//7Vr plasmid was subject to sequencing reaction. The sequence of PCR cloned 
HNT cDNA and the predicted amino acid sequence was shown in Fig. 4-4. 
Compared to the well recognized mRNA sequence with the NCBI accession number 
NM—016522, our results showed extra 33 nucleotides between the last two exons. 
Further sequence analysis confirmed that the extra 33 nucleotides were distributed in 
the middle of intron 6 (Fig. 4-4(G))，indicating that they made an extra exon through 
alternative splicing. The sequence of the new transcript variant had been submitted to 
NCBI and the online accession number is EF043567. The detailed transcription 
structures were shown in Fig. 4-4(G). 
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Fig.4-4. Characterization of tumor suppressor candidate HNT, 
(A). Schematic structure of the HNT promoter CpG island. Locations of the core 
promoter, exons 1 and 2 {filled rectangles) and the CpG sites in the CGI {short 
vertical lines). The start site of coding region (starts with ATG) was indicated by a 
curved arrow. The CGI, MSP and RT-PCR regions analyzed were indicated. 
(B). Broad expression of HNT in human normal adult and fetal tissues as detected by 
semiquantitative RT-PCR. Sk.M, skeleton muscle; LN, lymph node. 
(C). Representative expression of HNT by semiquantitative RT-PCR and promoter 
methylation analysis by MSP in various carcinoma cell lines. Immortalized normal 
epithelial cell lines NP69, NEl, NE3, Het-IA, HMEC, HMEpC, HEK293 and 
RHEK-1 {boxed) were used as normal controls. M, methylated; U, unmethylated. 
The presence of methylated PCR product indicated the presence of promoter 
methylation. HNT expression was widely downregulated in all kinds of tumor cell 
lines accompanied with promoter methylation but not in the immortalized normal 
epithelial cell lines. The expression inactivation in colon tumor cell line HCT116 
could be partially restored by genetic demethylation through double genetic knock 
out of DNMT 1 and DNMT3B (DKO) as indicated with white arrow. 
(D). Pharmacologic demethylation and induction of HNT expression in 
transcriptional silenced tumor cell lines accompanied with promoter methylation. 
Left, the reactivation of gene expression was checked by RT-PCR and the effect of 
demethylation was examined by MSP. Top, the cell lines before and after treatment 
with demethylation drugs (A: treated with 5-aza-2'-deoxycytidine alone; A+T: 
treated with 5-aza-2‘-deoxycytidine combined together with trichostatin A). Only six 
cell lines, HKl, MB231 HONEl, C666-1, Hep3B and BT549, showed different level 
of expression restoration in 15 cell lines checked. 
(E). The restriction map (1) and illustration of the major restriction sites of the HNT 
full length cDNA construct (2). The full length cDNA contained plasmid was 
digested with combination of Nhel and Kpnl and the expected 1130bp fragment 
appeared {short white arrow). On the (2) panel, the original sources of DNA 
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(G). Schematic transcript structure of gene HNT. Predicted exon-intron organization 
of alternative transcript identified by cDNA cloning of the HNT gene was presented. 
One extra exon 7 (E7) was shown. 
4.4 Further characterization of BARX2 
4.4.1 Tissue transcriptional expression panel 
The transcriptional expression profile of BARX2 in human adult tissues was 
examined by RT-PCR as shown in Fig.4-5(B). BARX2 was strongly expressed in 
most of human adult normal tissues including larynx, trachea and esophagus. BARX2 
did not show any expression or showed low level of expression in the adult tissue 
from skeleton muscle, spleen, bone marrow, heart and liver. 
4.4.2 Semiquantitative RT-PCR results in tumor cell lines 
The mRNA expression levels of BARX2 were studied in multiple tumor cell 
lines. The tumor types included NPC, ESCC, breast cancer, gastric cancer, cervical 
cancer, colon cancer, lung cancer, RCC and prostate cancer. HCC was excluded due 
to relative low level of BARX2 expression in normal adult liver. The immortalized 
normal epithelial cell lines NP69, NEl, NE3, Het-IA, HMEC, HMEpC, HEK293 
and RHEK-1 were used as normal controls for related cancers. The results were 
shown in Fig. 4-5(C). BARX2 showed relatively high frequency of expression 
downregulation in cervical cancer and RCC, 75% and 57% separately, yet 
uncommon downregulation in other examined tumor types. These results were 
summarized in Table 4-5. 
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Table 4-5 Summary of BARX2 expression downregulation and promoter 
methylation in tumor cell lines 
Samples RT-PCR Result MSP Result 
(Tumor cell (Frequency of 
lines) Frequency of totally Frequency of downregulation methylation) 
silenced (including silenced cell lines) 
NPC 1/6(17%) 1/6(17%) 3/6 (30%) 
ESCC 2/17 (12%) 5/17 (29%) 1/13 (8%) 
Gastric Cancer 1/11 (9%) 4/11 (36%) 5/11 (45%) 
Breast Cancer 1/8(13%) 3/8 (38%) 2/8 (25%) 
Cervical Cancer 1/4 (25%) 3/4 (75%) 1/4 (25%) 
Lung Cancer 0/5 (0) 2/5 (40%) 3/5 (60%) 
Colon Cancer 0/4 (0%) 1/4 (25%) Not done 
RCC 3/7 (43%) 4/7 (57%) 0/7 (0) 
Prostate Cancer 0/2(0) 2/2 (100%) 1/2 (50%) 
4.4.3 Promoter CpG island identiHcation and promoter methylation study 
The 5' promoter sequence of BARX2 was retrieved from Human Genome 
Browser Gateway database. Sequence comparison study illustrated that human and 
mouse BARX2 gene shared high similarity in the 1-kb region immediately upstream 
of the first exon. Further study using TF searching program TFSEACH discovered a 
cluster of regulatory elements in this region, including binding sites for Spl, binding 
motifs for basic helix-loop-helix proteins and Ets proteins. Typical CpG island was 
identified in the surrounding region by CpG Island Searcher tools. The identified 
CpG island lays over the whole exon 1 and has a high CpG sites density, with a G/C 
nucleotide percentage of 70.7% and an observed to expected CpG ratio of 0.95. The 
CpG sites distribution and the position of exon 1 were illustrated in Fig. 4-5(A). The 
promoter methylation statuses in the tumor cell lines and immortalized normal cells 
were examined by MSP with the primers as shown in Fig. 4-5(A). The MSP PCR 
results as shown in Fig. 4-5(C) demonstrated that BARX2 promoter methylation was 
rarely found in tumor cell line, which was consistent with uncommon expression 
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downregulation. Most of the cell lines with methylation detected showed BARX2 
expression downregulation. None of the immortalized normal epithelial cells showed 
methylation. The frequencies of methylation in different tumor types were 
summarized in Table 4-5. 
4.4.4 Transcription reactivation by demethylation treatment 
To study whether the consequences of BARX2 downregulation was associated 
with promoter hypermethylation, four cell lines with transcription inactivation 
accompanied with promoter methylation were subject to demethylation treatment, 
with 5-aza-2'-deoxycytidine alone or combined together with trichostatin A. The 
reactivation of gene expression was studied by RT-PCR and the effects of 
demethylation were examined by MSP as shown in Fig. 4-5 (D). The results revealed 
that the expression downregulation in C666-1, EC 109 and MB231 was significantly 
upregulated after the demethylation treatment. The demethylation effects in C666-1 
and EC 109 were obvious, obtaining an increase of the unmethylation allele 
amplification product. 
4.4.5 BARX2 full length cDNA cloning 
The full length cDNA of BARX2 was cloned into the pcDNA3.1(+) 
expression vector as described in chapter three. The major restriction sites and their 
relative positions around the insert were illustrated in Fig. 4-4(E-2). The clone was 
examined by restriction digestion with Smal and XhoL The cloning strategy allowed 
a bidirectional insertion of cDNA product. However, the Smal restriction site lying 
in the first one third part of the full length cDNA would help to identify the clone 
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with the right insertion direction. The restriction map was shown in Fig. 4-5 (E-1). 
The expected restriction fragments of 614 bp and 1092bp appeared. 
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Fig.4-5. Characterization of tumor suppressor candidate BARX2, 
(A). Schematic structure of the BARX2 promoter CpG island. Locations of the core 
promoter, exons 1 and 2 (filled rectangles) and the CpG sites in the CGI (short 
vertical lines). The start site of coding region (starts with ATG) was indicated by a 
curved arrow. The CGI, MSP and RT-PCR regions analyzed were indicated. 
(B). Transcriptional expression panel of BARX2 in human adult normal tissues as 
detected by semiquantitative RT-PCR. Sk.M, skeleton muscle; LN, lymph node. 
BARX2 was strongly expressed in most of human normal tissues but showed low or 
even undetectable expression in the adult tissues skeleton muscle, spleen, bone 
marrow, heart and liver. 
(C). Representative expression of BARX2 by semiquantitative RT-PCR and promoter 
methylation analysis by MSP in various carcinoma cell lines. The tumor types 
included NPC, ESCC, breast cancer, gastric cancer, cervical cancer, colon cancer, 
lung cancer, RCC and prostate cancer. Immortalized normal epithelial cells NP69, 
NEl, NE3, Het-IA, HMEC, HMEpC, HEK293 and RHEK-1 {boxed) were used as 
normal controls. M, methylated; U, unmethylated. The presence of methylated PCR 
product indicated presence of promoter methylation. The expression downregulation 
of BARX2 in tumor cell lines was generally uncommon. Accordingly, low 
frequencies of promoter merhylation were detected in tumor cell lines, but 
methylation was not found in normal immortalized epithelial cells. In specific cell 
line, the methylation was well correlated with expression. 
(D). Pharmacologic demethylation and induction of BARX2 expression. Left, the 
reactivation of gene expression was checked by RT-PCR and the effects of 
demethylation were examined by MSP. Top, the cell lines before and after treatment 
with demethylation drugs. A: treated with 5-aza-2‘-deoxycytidine alone; A+T: 
treated with 5-aza-2‘-deoxycytidine combined together with trichostatin A. BARX2 
expression in C666-1, EC 109 and MB231 was significantly upregulated 
accompanied with unmethylation specific PCR bands appeared in C666-1 and 
EC109. 
(E). The restriction map (1) and illustration of the major restriction sites of the 
BARX2 full length cDNA construct (2). The right directional insert was examined by 
restriction digestion with Smal and Xhol. The expected 614 bp and 1092bp 
restriction fragments appeared (short white arrows). On the (2) panel, the original 
sources of DNA fragments were indicated with specific shape of lines as indicated. 
The restriction sites used for digestion analysis were underlined. 
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4.5 Further study of other downregulated genes 
The transcriptional expression of some other tumor specific downregulated 
genes, FLIl and ADAMTS15, could also be fully or partially restored by 
demethylation treatment as shown in Fig. 4-2(C). Human P53AIP1 gene in my 
studied region has been reported to induce apoptosis. These interesting genes were 
also further studied and the results were shown as below. 
4.5.1 FLIl 
FLIl was downregulated in two of six NPC cell lines and two of three ESCC 
cell lines as shown in Fig. 4-2(A). Its transcription expression in normal tissues and 
tumor cell lines were examined by semiquantitative RT-PCR as shown in Fig. 4-6. 
The results revealed that FLIl was strongly expressed in all of the examined 
human normal adult and fetal tissues. The expression levels showed little difference 
in different tissues. Then FLIl expression in multiple tumor cell lines was checked. 
The tumor types included NPC, ESCC, HCC, breast cancer, gastric cancer, cervical 
cancer, colon cancer and lung cancer. The immortalized normal epithelial cell lines 
NP69, NEl and NE3 were used as normal controls. The results indicated that FLIl 
expressions were broadly downregulated in most tumor types examined. Notably, 
FLIl was downregulated in all the tumor cell lines in gastric cancer, cervical cancer 
and colon cancer. More than 60% of downregulations were also observed in ESCC, 
breast cancer and lung cancer. Oppositely, FLI was normally expressed in all of 
immortalized normal epithelial cells. Taken together, the FLIl expression 
downregulations were tumor specific. The FLIl expression inactivation in colon 
tumor cell line HCTl 16 could be partially restored by genetic demethylation through 
double genetic knock out of DNMTl and DNMT3B (DKO), indicating the role of 
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promoter methylation in the expression silence. The results were summarized in 
Table 4-6. 
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Fig. 4-6. Further characterization of FLU. 
(A). Broad strong expression of FLU in human normal adult and fetal tissues as 
detected by semiquantitative RT-PCR. Sk.M, skeleton muscle; LN, lymph node. 
(B). Representative expression downregulation of FLU by semiquantitative RT-PCR 
in various carcinoma cell lines. The expression levels of FLU were studied in NPC, 
ESCC, HCC, breast cancer, gastric cancer, cervical cancer, colon cancer and lung 
cancer. The immortalized normal epithelial cell lines NP69, NEl and NE3 were used 
as normal controls. FLI was normally expressed in all of immortalized normal 
epithelial cells (boxed). However, its expressions were widely downregulated in most 
examined tumor types. Moreover, the FLIl expression inactivation in HCTl 16 cell 
line could be partially restored by genetic demethylation through double genetic 
knock out of DNMTl and DNMTSB (DKO) as indicated by the white arrow. 
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Table 4-6 Summary of FLU expression downregulation in tumor cell lines 
Samples RT-PCR Result 
(Tumor cell 
lines) Frequency of totally Frequency of downregulation 
silenced (including silenced cell lines) 
NPC 2/6 (33%) 2/6 (33%) 
ESCC 4/17 (24%) 13/17(76%) 
HCC 3/13 (23%) 4/13(31%) 
Gastric Cancer 7/10 (70%) 10/10 (100%) 
Breast Cancer 3/9 (33%) 8/9 (89%) 
Cervical Cancer 2/4 (50%) 4/4 (100%) 
Lung Cancer 3/5 (60%) 3/5 (60%) 
Colon Cancer 3/3 (100%) 3/3 (100%) 
4.5.2 ADAMTSl 5 
ADAMTSl 5 was found totally silenced in one of six NPC cell lines, C666-1, 
and its expression could be restored by demethylation treatment. Therefore, its 
transcription expression levels were further studied in normal tissues and several 
types of tumor cell lines. Furthermore, the demethylation reactivation studies were 
also performed in some of the cells lines with downregulation. The results were 
illustrated in Fig. 4-7. 
ADAMTSl 5 was found to be broadly expressed in all normal adult tissues 
examined though at different levels. The expression in nasopharynx around tissues 
(larynx and trachea), and esophagus were very strong. Then ADAMTSl5 
transcription expression levels in multiple tumor cell lines were examined. The 
examined tumor types included NPC, ESCC, HCC, gastric cancer, breast cancer, 
cervical cancer, colon cancer, RCC and prostate cancer. The immortalized normal 
epithelial cell lines NP69, NEl, NE3, HMEC, HMEpC, HEK293 and RHEK-1 were 
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used as normal controls for related cancers. The detailed results were shown in Fig. 
4-7(B). Few downregulation cases were observed in NPC, ESCC, breast cancer, 
cervical cancer, colon cancer, RCC and prostate cancer cell lines. However, about 
70% of HCC and gastric cancer cell lines showed downregulation or even totally 
silencing of AD AMIS 15 when compared to its strong expressions in normal liver and 
stomach. The frequencies of downregulation in all tested tumor type were 
summarized in Table 4-7. To elucidate whether ADAMTS15 transcriptional 
expression downregulation was associated with promoter hypermethylation, several 
cell lines were subject to demethylation treatment with 5-aza-2‘-deoxycytidine alone 
or combined together with trichostatin A. The reactivations of gene expression were 
studied by semiquantitative RT-PCR. The results were shown in Fig. 4-7(C) and 
summarized in Table 4-7. All of the examined cell lines showed partial or fully 
expression restoration after the demethylation treatments, indicating an epigenetic 
expression downregulation mechanism. 
Table 4-7 Summary of ADAMTS15 expression downregulation in tumor cell 
lines and demethylation restoration 
RT-PCR Result 
Samples 
(Tumor cell lines) Frequency of totally Frequency of downregulation Upregulation by 
silenced (including silenced cell lines) A/A+T 
NPC 1/15(7%) 3/15 (20%) 1/1 
ESCC 0/17(0) 4/17 (24%) Not done 
HCC 3/13(23%) 9/13 (69%) 5/5 
Gastric Cancer 3/11 (27%) 8/11 (73%) 2/2 
Breast Cancer 0/8(0) 2/8 (25%) Not done 
Cervical Cancer 0/4 (0) 1/4 (25%) Not done 
Colon Cancer 0/4 (0) 1/4 (25%) Not done 
RCC 0/7(0) 1/7(14%) Not done 
Prostate Cancer 0/3 (0) 0/3 (0) Not done 
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Fig. 4-7. Further characterization of ADAMTS15. 
(A). Broad expression of ADAMTS 15 in human normal adult tissues detected by 
semiquantitative RT-PCR. LN，lymph node. 
(B). Representative expression of ADAMTS 15 by semiquantitative RT-PCR in 
various cancer cell lines. The immortalized normal epithelial cell lines NP69, NEl, 
NE3, HMEC, HMEpC, HEK293 and RHEK-1 {boxed) were used as normal controls 
for related cancers. Few NPC, ESCC, breast cancer, cervical cancer, colon cancer, 
RCC and prostate cancer cell lines showed ADAMTS 15 downregulation. However, 
frequent expression downregulation cases were observed in gastric and HCC cell 
lines compared to normal tissues indicated above. 
(C). Pharmacologic demethylation and induction of ADAMTS 15 expression. The cell 
lines before and after treatment with demethylation drugs (A: treated with 5-aza-2'-
deoxycytidine alone; A+T: treated with 5-aza-2'-deoxycytidine combined together 
with trichostatin A) were shown as indicated. Semiquantitative RT-PCR results 
indicated that all of the examined cell lines showed partial or fully expression 
restoration after the demethylation treatments. 
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4.5.3 P53AIP1 
P53AIP1 was previously reported to be able to induce apoptotic cell death 
when ectopically expressed. (Oda et al. 2000) To further examine whether 
inactivation of P53AIP1 is involved in tumor initiation and progression, the 
transcriptional expression of P53AIP1 was studied in human normal tissues and 
several tumor cell lines as shown in Fig. 4-8. 
Semiquantitative RT-PCR reactions were performed using the primer pair as 
indicated in Fig. 4-8(A). The human normal adult and fetal tissue expression profile 
as shown in Fig. 4-8(B) revealed that P53AIP1 expression was tissue specific. 
Moderate to relatively strong levels of expressions were detected in nasopharynx 
around tissues (larynx and trachea), esophagus, breast, cervix, prostate, brain and 
testis, but very low or undetectable expressions were found in most other normal 
tissues. The expression levels of P53AIPl in both NPC and ESCC cells were studied 
with immortalized normal epithelial cells NP69, NEl and NE3 as normal controls. 
The results shown in Fig. 4-8(C) illustrated that P53AIP1 did not show obvious 
downregulation in these tumor cell lines. 
In the process of differential expression study, a PCR product with 
unexpected smaller size, as indicated by the arrows on Fig. 4-8(D), was found in 
most of normal tissues and some of tumor cell lines with P55^/P7expression. The 
smaller size products amplified from normal tissue larynx and ESCC cell line 
HKESC3 were excised from the agarose gel. The products were purified and subject 
to direct sequencing with the RT-PCR primers. The same sequencing results were 
obtained as shown on the left panel of Fig. 4-8(D). Compared to the expected PCR 
product, the products with smaller size lack 60bp nucleotides located on the 
beginning of exon 2, indicating the presence of new transcription variant. 
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Fig. 4-8. Further characterization oiP53AIPl, 
(A). Schematic transcript structure of gene P53AIP1 according to previous study. 
(Oda et al. 2000) Exon-intron organization and alternative splicing of the P53AIP1 
gene were presented. Left, the sequence database accession number, the size of 
transcript variants and corresponding coding proteins (isoforms a, (3 and y); Top, the 
exons and introns. The protein coding regions for the characterized transcripts were 
also shown as indicated. For the exon E2y of transcription variant AB045832, only 
parts of its sequence were shared by the other two variants. Partial structure of the 
identified new transcription variant was presented. The P53 binding site was located 
at intron 1 as indicated. The positions of RT-PCR primers were also indicated by 
arrows. The length of lines did not represent the actual length. 
(B). Tissue specific expression of P53AIP1 in human normal adult and fetal tissues 
detected by semiquantitative RT-PCR. Sk.M, skeleton muscle; LN, lymph node. 
(C). Representative expression of P53AIP1 in NPC, ESCC cell lines with 
immortalized normal epithelial cells NP69, NEl and NE3 {boxed) as normal controls. 
(D). The sequence of the transcript variant lacking 60bp nucleotide at the beginning 
of exon2. The lacked sequence was boxed. And the RT-PCR primers sequence was 
underlined. The right panel showed the extra PCR product {white arrows) subject to 
direct sequencing in the indicated samples. 
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Chapter Five: Discussion 
Tumorigenesis and TSGs 
The initiation and progression of cancer is a multistage process. The serial changes 
on the primary normal cells would include immortalization, transformation and 
metastasis sequentially. After immortalization process, the cells could divide 
indefinitely. However, these cells continue to adhere to substratum, require serum for 
growth, and are growth inhibited by cell-cell contact. After completion of 
transformation process, the cells are independent of anchorage, serum and contact 
inhibition. The cells also change their shape and grow rounding up. At this phase, the 
transformed cells may form solid tumors. After gaining the ability of metastasis, the 
cells become mobile and can migrate to form new colonies. Through these long term 
processes, the defects in various cancer genes accumulate and these increased defects 
confer more and more growth advantages of the cells. The descendent cells obtaining 
more growth advantages will grow much faster than other cells and dominate the 
population gradually. The involved cancer genes include oncogenes and TSGs. 
Oncogenes and TSGs act their functions oppositely. An oncogene results from a 
gain-of-function mutation of a proto-oncogene that generates a tumorigenic product. 
Contrarily, mutations on a tumor suppressor cause a loss-of-function in the ability to 
restrain cell growth. According to revised Knudson's two hit model, one or both 
alleles of a class II TSG might be inactivated through epigenetic mechanism 
including promoter CpG island hypermethylation. (Jones and Laird 1999) It has been 
discovered that the methylation statuses of the promoter CpG sites are correlated 
with gene transcription activity. Normally, most of the CpG sites in the gene 
promoter regions are unmethylated, allowing active transcription. However, in 
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cancer cells, aberrant promoter methylation has been found in cancer related genes, 
especially TSGs, which is associated with transcriptional silencing of the 
corresponding genes.(Baylin and Herman 2000) In my current study, the tumor 
specific promoter methylation was used as markers for the identification of candidate 
TSGs. 
Spurious promoter methylation during cell culture 
In this study, the major source of DNA and RNA used was from developed 
carcinoma cell lines and immortalized normal epithelial cell lines. The major 
advantage of using DNA/RNA from cancer cell lines is the availability of 
homogeneous cancer cell populations. This benefit is especially important for PCR 
based transcription expression level study by semiquantitative RT-PCR and 
methylation study by MSP, because a little bit of impure normal cell RNA/DNA 
might influence the result. 
However, there is also a reasonable concern about using cell lines on DNA 
methylation studies since some de novo methylation of cancer related genes might be 
developed during the in vitro passage process of cell lines. It has been reported that 
permanent lines of cultured cells, either derived from tumors or normal tissues, can 
be methylated at the majority of CpG islands associated with tissue-specific genes, 
while these sequences remain unmethylated in all normal somatic tissues regardless 
of expression status. (Walsh and Bestor 1999) Undoubtedly, constant and intensive 
selection pressure is imposed on cultured cells with passages. This might lead to 
silencing of the genes that restrict proliferation or promote differentiation to adapt to 
the culture surroundings. As a result, gene silencing by CpG island methylation is 
much more common in culture cells than in the cells from primary tumors. (Bestor 
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2003) Therefore, it is very important to confirm the presence of methylation in 
primary tumors when some genes were found to be silenced by promoter methylation 
in tumor cell lines. 
The whole strategy of this study 
Genetic alterations were firstly recognized as the primary changes responsible for the 
functional inactivation of TSGs. These changes include loss of copy number changes 
such as homozygous deletions and LOH at specific chromosome regions. As 
mentioned previously, inactivations of multiple functional TSGs are usually involved 
in the initiation and progression of cancer. Therefore, the functional TSGs reside on 
the chromosome loci with copy number losses in tumors. Array based CGH has been 
well recognized as a powerful technique to detect regional DNA copy number 
alterations in a whole genome wide fashion. To identify novel TSGs silenced by 
aberrant promoter methylation, an integration of genomic and epigenetic analyses 
were employed. A 1-Mb array-based CGH was carried out previously to detect copy 
number aberrations, thus TSG residing loci, in a panel of NPC and ESCC cell lines. 
Frequent deletions at chromosome 1 Iq24.2-q25 were found. Furthermore, deletions 
on chromosome Ilq24.2-q25 had also been reported in NPC, ESCC and multiple 
other carcinomas including breast carcinoma, ovarian cancer and lung cancer et al. as 
described in literature review chapter. These well established specific deletions in 
tumors at chromosome Ilq24.2-q25 indicate the presence of critical TSGs. Based on 
the array-CGH data, the MDR was defined between BAC clone bA168K9 and 
bA419F8, a 6 Mb chromosome region in chromosome 11. 
Critical TSGs are frequently inactivated in tumors to facilitate tumor cell 
growth. It is well recognized that gene expression silencing at transcriptional level is 
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one of the most efficient gene inactivation strategies. Hence, differential expression 
profile at mRNA level in tumors and corresponding normal tissues usually leads to 
the finding of frequent tumor specific downregulation on the putative TSGs. In my 
study, the differential transcriptional expression profile was used as a strategy to 
narrow down the candidate genes for further study. The transcription expression 
studies on all the genes in the MDR area led my research to focus on six specific 
genes. All the six genes either were found to be frequently specifically 
downregulated in tumor cell lines (ADAMTS8 and HNT) or had been suggested to 
closely correlate with tumorigenesis {FLU, BARX2, ADAMTS15 and P53AIP1). The 
following three genes were not focused. OPCML were found totally silenced in all of 
the examined tumor cell lines specifically, yet it has already been studied in NPC, 
ESCC and multiple other carcinomas by my labmate. Gene LOC387821 was found 
to be silenced in two NPC cell lines and two ESCC cell lines examined. But this gene 
is still a predicted gene. Its full length cDNA and protein sequence had not been 
confirmed. Another gene ST 14 also showed downregulation in one of ESCC cell 
lines. Nevertheless, this gene had been intensively studied in multiple carcinomas 
and was well characterized. 
In the differential expression study, adult normal tissue testis was used as a 
positive control since most human genes were supposed to be expressed in testis. 
Moreover, the amplification results in testis could also be used to evaluate the 
working efficiency of RT-PCR primers. Adult normal tissue larynx and trachea were 
used as substituted normal controls for NPC due to lack of normal nasopharynx 
tissue. Normal larynx and trachea tissues are much easier to obtain and commercially 
available. They are anatomically adjacent to nasopharynx and histologically 
constituted with similar cell types. Hence, normal larynx and trachea tissues are 
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supposed to possess similar gene expression patterns as nasopharynx. Normal adult 
esophagus tissue was used as normal control for ESCC. 
ADAMTS8 
In the process of tumor progression, angiogenesis is necessary for the 
transition from a small harmless cluster of cells to a deadly large tumor. In addition, 
angiogenesis is also required for the spread of a tumor. ADAMTS8, which encodes a 
potent inhibitor of angiogenesis, (Vazquez et al. 1999) is believed to play important 
roles in cancer pathogenesis and therapy. Indeed, frequent expression 
downregulation of ADAMTS8 has been identified in NSCLC, brain tumors and breast 
carcinomas with respect to nonneoplastic corresponding normal tissues, though 
different major inactivation mechanisms were suggested. (Dunn et al. 2004; Dunn et 
al. 2006; Porter et al. 2006) All of the reporters proposed that the tumor specific 
ADAMTS8 downregulation was involved in the tumorigenesis. 
In my study, more than 60% of cell lines consistently showed ADAMTS8 
expression downregulation in all tumor types examined. Notably, ADAMTS8 was 
found totally silenced in all six tested NPC cell lines, indicating especially important 
roles of ADAMTS8 inactivation in the pathogenesis of NPC. It is worthy pointing out 
that ADAMTS8 downregulation in NPC was not tissue specific but tumor specific, 
because it was moderately expressed in immortalized normal nasopharyngeal 
epithelial cell line NP69. 
Coupled with expression downregulation, aberrant promoter methylation was 
also detected in tumor cell lines from different tumor types, though at different 
frequencies. As expected, the ADAMTS8 promoter methylation statuses were closely 
correlated with its transcriptional expression level. In detail, the presence of 
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methylated alleles accompanied with absence of unmethylated alleles was always 
connected with total expression silencing. Oppositely, the presence of expression 
was always accompanied with the presence of unmethylated alleles. Furthermore, the 
demethylaition treatment tests, either pharmacologic or genetic, usually resulted in 
ADAMTS8 expression restoration. These results might indicate the significance of 
aberrant promoter methylation in the inactivation of ADAMTS8 during tumorigenesis. 
To further investigate whether the gene silencing associated promoter methylation 
indeed exists in the primary tumors or not, the ADAMTS8 promoter methylation 
statuses were examined in multiple clinical primary tumor samples. Consistently, 
aberrant ADAMTS8 promoter methylation was found in NPC and gastric primary 
tumors. Furthermore, this methylation was not found in either immortalized normal 
epithelial cell lines or nasopharynx tissue from nonmalignant nasopharyngitis 
patients, indicating the promoter methylation was tumor specific. However, a 
reasonable concern is that much lower frequency of ADAMTS8 promoter methylation 
was observed in primary tumor samples than in corresponding tumor cell lines. For 
example, all examined NPC and 55% gastric cancer cell lines showed ADAMTS8 
promoter methylation, but the percentage were 12% and 6% separately in primary 
tumor samples. Moreover, none of the examined primary tumor samples from ESCC, 
breast and colon cancer patients showed ADAMTS8 promoter methylation. The 
tremendous difference might be induced from the in vitro passage process of cell 
lines as described previously. If that is true, it might suggest that inactivation of 
ADAMTS8 would confer more growth advantage of cancer cells. In this study, the 
ectopic expression of ADAMTS8 in tumor cell lines indeed suppressed the formation 
of colonies significantly. 
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Nevertheless, undoubtedly, other factors are also involved in the regulation of 
ADAMTS8 transcriptional expression. In HCC, 11 of 13 cell lines showed 
downregulated ADAMTS8 expression, but only one cell line had promoter 
methylation. These results suggested that multiple genetic changes such as genomic 
deletions or epigenetic changes such as histone modifications were also involved in 
the downregulation of ADAMTS8 expression. The involvements of histone 
modifications could be supported by demethylation treatment data. Such as in NPC 
cell line CNE2, C666-1 and HKl, much higher ADAMTS8 expression levels were 
observed in case of combining 5-aza-2‘-deoxycytidine and trichostatin A than in case 
of applying 5-aza-2‘-deoxycytidine alone for the demethylation treatment. Since 
genomic deletions in the studied chromosome region were found in the array CGH 
tests, deletions were screened at the two borders of ADAMTS8 intron 1 through 
multiplex genomic PCR in this study. No homozygous deletion was found. But 
obvious decrease of F/IntlR amplification product was observed in cell line C666-1, 
suggesting presence of heterozygous deletion. This heterozygous deletion could be 
further confirmed by alleles differential presenting tests based on sequence 
difference between the two alleles at the microsatellite or polymorphisms sites. Since 
ADAMTS8 gene encompasses a 24 kb genomic region, it is possible that homozygous 
deletions events on ADAMTS8 gene might exist on loci other than the screened intron 
1 borders. Therefore, the sequence beyond all other exons (exon 3 to exon 8) could 
be further studied for an intensive deletion screening. 
HNT 
HNT gene encodes a member of the IgLONs, an immunoglobulin subfamily 
of GPI anchored cell adhesion molecules. The other three members of IgLONs in 
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human are 0PCML{\\ql5), LSAMP{^qU2) and N E G R I T h e knowledge 
on the specific functions of these proteins is still limited. The previous functional 
studies were mainly performed in chick and rat models with the concern about 
neurodevelopment. These studies suggested that the IgLONs might have important 
roles in cell adhesion and cell-cell recognition, mediated by both homo- and 
heterophilic interactions.(Gil et al. 1998) 
The IgLON subfamily has been linked to cancer recently since two of its 
members, OPCML and LSAMP, were proposed as candidate tumor suppressors. 
OPCML has been shown to exhibit tumor suppression functions in an ovarian cancer 
both in vitro (by cell growth assay and cell aggregation assay) and in vivo (by nude 
mice intraperitoneal and subcutaneous tumorigenicity assays).(Sellar et al. 2003) On 
the other hand, ectopic expressions of LSAMP in clear cell renal cell carcinoma lines 
were also able to inhibit cell proliferation. (Chen et al. 2003) Moreover, aberrant 
promoter CpG island hypermethylation was found to be the major mechanism 
involved in the inactivation of both of the genes in studied tumors. 
In this study, HNT was found to be widely expressed in normal adult tissues 
and fetal tissues by semiquantitative RT-PCR, though at different levels. 
Dramatically, this gene was also found widely transcriptionally silenced in multiple 
tumors cell lines. It is worth pointing out that HNT was found totally silenced in all 
of the tested NPC and ESCC tumor cell lines, but with strong expression in normal 
larynx, trachea and esophagus tissues. These results suggested that HNT might play 
important roles in the tumorigenesis of these two cancer types. HNT was shown 
moderately or strongly expressed in all three esophageal epithelium derived 
immortalized cell line NEl, NE3 and Het-IA and normal adult esophagus tissue, 
indicating HNT silencing in ESCC cell lines is tumor specific. HNT was also shown 
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to be silenced in normal nasopharynx epithelium derived immortalized cell line 
NP69. NP69 was established from primary cultures of nasopharyngeal epitheliums 
by introduction of SV40T oncogene. The immortalized cell line still maintained 
many characteristics of normal nasopharynx cells, such as the keratin expression 
profile and response to TGFp inhibition. It had been proved to be non-tumorigenic 
and exhibit anchorage-dependent growth. However, NP69 is not a completely normal 
cell line. It contains multiple genetic alterations obtained in the process of 
immortalization, and some of these alterations have been described in NPC. The 
group developed NP69 also performed CGH analysis on this cell line and found 
broad loss of chromosome material in 1 lql4-qter.(Tsao et al. 2002) This might 
explain the downregulation of HNT in NP69. (Downregulation of ADAMTS8 and 
BARX2 in NP69 might also be explained.) On the other hand, it could not be 
excluded that HNT is tissue specific silenced in nasopharynx. HNT was found 
strongly expressed in the adjacent tissue larynx and trachea, but it could not conclude 
that HNT is also expressed in nasopharynx. To check the expression status in the 
nasopharynx cells, in situ immunohistochemistry analysis could be performed. 
The mRNA expression of HNT in tumors was also studied previously in 
brained tumors and epithelial ovarian cancer and the results suggested that HNT was 
also downregulated in nervous system tumors. (Liu et al. 2004) Nevertheless, HNT 
transcriptional expression was shown to be upregulated in most of the epithelial 
ovarian cancer primary samples compared with normal human ovary tissues. 
Furthermore, the expression elevation of HNT is shown to be correlated with serious 
carcinoma. This diverse expression elevation might be due to the unique characters 
of ovarian cancer. It has been well recognized that human normal ovarian 
epitheliums are not fully differentiated, retaining certain mesenchymal characteristics. 
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The process of malignant transformation in ovarian epitheliums is characterized by a 
differentiation process, in contrast with most other tumor types.(Auersperg et al. 
2001) 
HNT promoter CpG island methylation study (MSP) showed that promoter 
methylation is broadly present in multiple tumor cell lines but rarely present in 
normal immortalized cell lines (only NP69 showed moderate methylation level). The 
methylation is present in most expression silenced cell lines. Furthermore, the 
unmethylation specific PCR band was usually present in the cell lines with HNT 
expression. These results provided evidences that promoter CpG island methylation 
might play a role in the regulation of transcription expression. Nevertheless, it is 
obvious that some other factors are also involved in the expression regulation of this 
gene. For example, in RCC cell line A498, gastric cell line YCC16 and lung cell line 
HI299, the presence of promoter hypermethylation seems do not affect the 
expression significantly. Moreover, the pharmacological and genetic demethylation 
study also demonstrated the existence of other important factors on the transcription 
regulation. After drug demethylation treatment, only two cell lines showed obvious 
expression restoration and a few other cell lines showed mild reactivation, while 
most of other cell lines did not show any expression upregulation. HNT promoter 
was found hypermethylated in colorectal cancer cell line HCTl 16 and the expression 
was silenced. The expression was only slightly but not fully restored by genetic 
demethylation through double knockout of both DNMTl and DNMT3B (DKO cell 
line). One possible explanation is that one or multiple other transcription factors 
might be significantly involved in the transcription activity regulation of HNT, while 
the expression of these critical transcription factors might be regulated directly by 
promoter methylation. 
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In the process of HNT full length cDNA cloning, a new transcript variant 
with an extra amino acids encoding exon was firstly found. The exon-intro 
organization and the encoding protein were predicted. However, the sequence 
obtained is not the complete mRNA sequence. To get the full mRNA sequence of the 
new transcript variant, 5' RACE and 3' RACE could be performed. 
BARX2 
BARX2 is a homeobox transcription factor. Homeodomain transcription 
factors regulate diverse cellular behaviors including adhesion, migration, 
proliferation, differentiation and apoptosis. In most cases, however, the identities of 
the target genes that link the homeodomain proteins to these regulation processes 
have not been elucidated. It is found that BARX2 prefers to regulate gene expression 
by binding to DNA elements containing paired TAAT motifs that are separated by a 
poly(T) sequence. Furthermore, many functionally binding sites for BARX2 were 
identified in the regions outside promoters of target genes, particularly in introns, 
suggesting that BARX2 binding involved transcription activation might function 
through long range interactions that involve looping of chromatin to bring distal 
elements within proximity of gene promoters. In a recent study, about 60 potential 
genomic binding sites of BARX2 in breast cancer MCF7 cells were identified by 
chromatin immunoprecipitation. These sites are associated with genes involved in 
cytoskeletal organization and cytokinesis, cell adhesion, growth factor signaling and 
transcription. (Stevens et al. 2004) Other previous studies indicate that murine Barx2 
influence cellular processes that control cell adhesion and remodeling of the actin 
cytoskeleton and chondrogenesis.(Meech et al. 2003) 
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Human BARX2 gene had been described as a functional tumor suppressor 
gene in ovarian cancer. BARX2 is expressed in normal ovarian surface epitheliums 
but silenced in several ovarian cancer cell lines including OAW42. Ectopic 
expression of BARX2 in OAW42 was able to inhibit cell migration, invasion as well 
as adhesion and cause cell accumulation in S phase of the cell cycle. This function 
might be correlated with cadherin 6 expression upregulation which is induced by 
BARX2.(Sellaret al. 2001) 
In my study, BARX2 was found strongly or moderately expressed in most of 
adult normal tissues. Further study showed that BARX2 transcription was silenced in 
several cancer cell lines but the percentage was not high. Promoter region CpG 
island methylation study found that the aberrant methylation was present in most cell 
lines with transcription silencing. Furthermore, the data showed that BARX2 
expression downregulation could be upregulated by demethylation treatment. These 
results suggest that aberrant promoter hypermethylation plays a major important role 
in the tumor specific transcription inactivation of BARX2. Since the tumor 
suppression activities of BARX2 had been demonstrated previously as described, it 
could be supposed that aberrant hypermethylation in BARX2 gene promoter region is 
correlated with tumor initiation and progression. 
FLIl 
FLIl is a member of Ets transcription factor family and binds to DNA target 
in a sequence specific manner. The previous studies indicated that aberrant activation 
of FLIl is involved in malignant transformation. The proposed mechanism is through 
inhibition of apoptosis, block of terminal differentiation and acceleration of 
proliferation.(Truong and Ben-David 2000) These evidences indicated that FLIl acts 
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as a potential oncogene character in the process of tumorigenesis. In my study, the 
tissue expression profile examination found FLIl was strongly expressed in all tested 
normal tissues. Expression dysregulations of putative oncogenes are usually over 
expressed in cancer. However, FLIl transcription expression was found broadly 
downregulated in multiple carcinomas cell lines, especially in gastric cancer and 
breast cancer. These results suggested that expression silencing of FLI is also 
involved in tumorigenesis, but might work through an alternative mechanism. 
ADAMTS15 
The expression status of ADAMTS 15 has been reported as an independent 
predictor of prognosis for breast cancer patients and significantly correlated with 
tumor progress. Low mRNA expression level of ADAMTS 15 was correlated with 
high stage tumors and poorer survival. In my study, ADAMTS 15 was found widely 
expressed in adult normal tissues. In tumor cell lines, few downregulation cases were 
identified in NPC, ESCC, breast cancer, cervical cancer, colon cancer, RCC and 
prostate cancer cell lines. However, ADAMTS 15 was found to be frequently 
downregulated in HCC and gastric cancer cell line, indicating its different roles in 
the tumorigenesis of different tumor types. More study revealed that all of the 
examined downregulation cases could be upregulated after demethylation treatment, 
indicating that epigenetic inactivation mechanisms are extensively involved. Further 
studies on the primary tumor samples and the functional studies are needed, and this 
will help elucidate the significance of dysregulation of this gene in tumor. 
P53AIP1 
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P53AIP1 has been characterized as an important downstream target of p53 
tumor suppressor and is induced directly by p53 in case of DNA damage. (Oda et al. 
2000) Three transcription variants of P53AIP1 corresponding with three isoforms (a, 
B and y) have been identified. The a and B forms of P53AIP1 are localized in the 
mitochondria and can induce apoptosis directly through dissipation of mitochondria 
membrane potential and release of cytochrome c from mitochondria. The expression 
of P53AIP1 and P53AIP1-induced apoptosis are closely correlated with 
phosphorylation of p53 at Ser46, indicating that P53AIP1 actually plays important 
roles in mediating p53-dependent apoptosis. Moreover, P53AIP1 interacts with bcl-2, 
an inhibitor of apoptosis, in mitochondria. Overexpression of bcl-2 was shown to be 
able to block the proapoptotic activity of P53AIP1. The application of ectopic 
expression of P53AIP1 for cancer treatment was also suggested.(Matsuda et al. 2002) 
All these findings suggested that P53AIP1 might be a very important tumor 
suppressor in that it is crucial for the regulation of p5 3-dependent DNA damage-
signaling pathways and disruption of P53AIP1 functions in p53-mediated apoptosis 
could play an important role in cancer development. 
In my study, P53AIP1 was found selectively expressed in several adult 
normal tissue including esophagus, larynx, trachea, brain, and strongly expressed in 
testis and cervix. The expected 289bp product was relatively stably expressed in 
most of NPC cell line and all ESCC cell lines. A 229bp unexpected product was also 
found in almost all of the normal tissues with P53AIP1 expression. The sequencing 
results illustrated that this unexpected product is another new transcription variant 
with alternative splicing lacking the first 60 nucleotides of exon2. The full length 
cDNA of this transcript variant could be obtained by further 5' RACE and 3' RACE. 
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It is interesting to note that this new variant was silenced in most of NPC and ESCC 
cell lines. 
Significance of the findings 
In this thesis, epigenetic inactivation of several candidate TSGs and cancer 
related genes have been identified in NPC, ESCC and multiple other carcinomas. 
The significance of the findings would include as follows. 
Firstly, the identification of the candidate TSGs or cancer-related genes 
would lead to better understanding of the pathogenesis of NPC, ESCC and other 
cancers. For example, ADAMTS8 was found frequently epigenetically silenced in 
NPC. The previous functional studies indicated that it is a putative antiangiogenic 
factor. Current tumor cells growth suppression study showed that ectopic expression 
of ADAMTS 8 could significantly suppress colony formations in NPC cell line 
HONEl. The finding would help elucidate how antiangiogenesis related gene 
inactivation would be involved in NPC initiation and progression. HNT was found 
silenced at transcription expression level in all examined NPC and ESCC tumor cell 
lines. Further functional and mechanism study might elucidate the exact biological 
function of this gene and how this gene plays a role in tumorigenesis. In addition, 
epigenetic progression has been found to parallel the histological changes. Hence, the 
promoter methylation changes identified on specific genes in tumors would lead to 
better understanding on the sequential molecular changes during the process of tumor 
progression. An intensive examination was performed recently on the promoter 
methylation statuses of a set of putative TSGs in ESCC tumors at different stages. 
The study found that the acquisition of aberrant TSG hypermethylation is similar to 
the classic gene mutation accumulation occurring during tumor progression. The 
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number of genes methylated in individual lesions increased as the cellular atypia 
increased. Furthermore, during the multistep process, the epigenetic changes on some 
specific genes often appeared on the early stage whereas the changes on other 
specific genes were found typically later.(Guo et al. 2006) 
Secondly, the tumor specific promoter methylation on the studied genes could 
serve as superior tumor markers on cancer screening, early detection and prognosis 
prediction. Detection of promoter CpG island hypermethylation of a group of 
specific genes offers several advantages compared to detection of other DNA 
alterations in cancer. Aberrant DNA methylation represents a stable tumor specific 
alteration that can be readily detected, without reference to gene expression level. 
Once a tumor cell has acquired methylation of some specific genes, this tumor 
specific methylation pattern will generally not be lost and is often enhanced during 
disease progression.(Markl et al. 2001) Genomic mutations such as point mutation 
often occur at different sites within a given gene in individual tumors and they are 
time consumable and expensive to detect. Other frequent chromosome changes in 
cancer, such as allelic loss, constitute the loss of detectable signal changes, such as 
loss of heterozygosity. However, DNA methylation occurs mainly at specific CpG 
islands within the promoter regions of specific genes. Moreover, the gain of 
methylation changes constitutes a gain of positively detectable signal changes. 
Aberrant DNA methylation can be detected with high sensitivity and 
specificity. Applying a quantitative methylation assay MethyLight, a single 
hypermethylated allele with a background of 10,000 unmethylated alleles can be 
detected.(Eads et al. 2001) The detection results can be verified by direct sequencing 
of the amplified products. This offers great merits in the use of cancer screening and 
minimal residue diseases detection. For example, it has been recently demonstrated 
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that aberrant promoter methylation of ERa and pl5INK4b could be detected in most 
of acute myeloid leukemia (AML) diseases samples but rarely found in control 
nonmalignant diseases. Furthermore, the methylation levels on these two genes can 
be quantitatively determined on different time points in the clinical remission stage 
AML patients and the serial methylation level changes can help predict the relapse 
risk powerfully.(Agrawal et al. 2007) We can believe that the methylation detection 
based prediction results can be more accurate and can help find the relapse at earlier 
time before the clinical diagnosis because many more other TSGs could be added to 
the gene combination lists to optimize the results. 
Based on the merits of aberrant DNA methylation detection as described 
above, several possible noninvasive ways can be applied to obtain DNA from 
patients for DNA methylation examinations. The most efficient method to detect 
aberrant DNA methylation is to examine DNA directly from the sites where the 
cancer occurs. For example, a series of studies have been reported to perform NPC 
detection with nasopharyngeal brushing samples,(Tong et al. 2002) colorectal cancer 
detection by stool,(Dong et al. 2001) and lung cancer detection by 
sputum.(Palmisano et al. 2000) Aberrant promoter methylation in tumor-derived 
DNA has also been detected in the serum or peripheral blood of some patients. 
Several studies proved the presence of free DNA derived from solid tumors in the 
blood stream of cancer patients. In NPC, epigenetic changes have been found 
frequently. Furthermore, the high aberrant promoter methylation detection rates have 
been found in the non-invasive screening studies of NPC patients or in the detection 
of residual carcinoma after treatment. For example, high frequency of DAPK 
promoter hypermethylation was found in the plasma and buffy coat DNA in NPC 
patients.(Wong et al. 2002) 
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Thirdly, the finding of promoter hypermethylation in cancers might also 
contribute to the development of new cancer therapeutic strategies. Previous studies 
found that 5-azacytidine was able to induce several differentiated cell phenotypes in 
undifferentiated mouse embryo cell lines.(Taylor and Jones 1979) Lately it was 
shown that this drug and its deoxy version, 5-aza-2'deoxycytidine could trap DNMT 
enzyme in a covalent complex with DNA and result in a loss of DNA methylation 
with each round of cell division.(Juttermann et al. 1994) In the last decades, these 
drugs have been used as anti-cancer agents since they can reverse epigenetic changes 
and restore tumor suppressor gene function to a cell. Bender et al. firstly reported 
that treatment with DNA methylation inhibitors can restore the activities of dormant 
genes such as pi6 and decrease the growth rate of cancer cells in a heritable 
fashion.(Bender et al. 1998) The reactivation of the expression and function of other 
critical tumor suppressors by demethylation drug treatment was reported in 
succession. Recent years, this type of drugs have been used in clinical trials in 
multiple carcinomas including NPC.(Wijermans et al. 2000; Chan et al. 2004) In my 
project, ADAMTS8 is a potent angiogenesis inhibitor working more efficiently than 
THBSl and endostatin. But it is frequently inactivated in NPC through aberrant 
promoter hypermethylation. Reactivation of this protein might help suppress tumor 
growth efficiently. Hence, ADAMTS8 has the potential to serve as a novel new 
therapeutic target in NPC. 
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Appendix I: Reagents Preparation Recipe 
LB medium 
Per liter: 
To 950 mL of deionized H2O, add: 
tryptone 10 g 
yeast extract 5g 
NaCl lOg 
Shake until the solutes have dissolved. Adjust the pH to 7.0 with NaOH. Adjust the 
volume of the solution to 1 liter with deionized H2O. And sterilize by autoclaving for 
20 min at 15 psi on liquid cycle. Suitable concentration of desired antibiotic would 
be added before use. 
LB agar plates 
Per liter: 
To 950 mL of deionized H2O, add: 
tryptone 10 g 
yeast extract 5g 
NaCl lOg 
agar 15g 
Shake until the solutes have dissolved. Adjust the pH to 7.0 with NaOH. Adjust the 
volume of the solution to 1 liter with deionized H2O. And sterilize by autoclaving for 
20 min at 15 psi on liquid cycle. After cooling down to the temperature about 55 °C, 
suitable concentration of desired antibiotic was added and mix well. LB agar plates 
were then prepared by pouring the mixture to 90mm Petri-dishes, with about 15ml 
for each plate. 
Solution I 
Consisted of 50mM glucose, 25mM Tris-HCl (pH8.0) and lOmM EDTA. The 




Consisted of 200mM NaOH and 1% SDS, freshly prepared with 2 M NaOH and 10% 
SDS before use. 
Solution III 
Consisted of 3M potassium acetate (pH5.2), prepared by mixing 60ml of 5M KOAc 
with 11.5ml Glascial acetic acid and 28.5ml H20. 
SOX TAE buffer 
SOX TAE buffer was prepared as dissolving 242g of Tris Base, 57.1ml of glacial 
acetic acid and 100ml of 0.5M EDTA (pH8.0) in ddH20 to a final volume of IL. 
6X DNA loading buffer 
6X DNA loading buffer consisted of 0.25% (w/v) bromophenol blue and 40% (w/v) 
sucrose in ddH20. 
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Appendix II: PCR Primers for cDNA Cloning 
Primer Name Sequence Product size 
Primers for ADAMTS8 cDNA cloning 
— M T S 8 F - 1 酵 � � w , 綠 , � „ , 
ADAMTSSFclonla CCTTGCACCCGATTGATTCC 827 
ADAMTS8R1 AGAAGGCAGCCATGGACGCA 
ADAMTS8F CGAGTAGGACCAAGCGGTT 789 
ADAMTSSRclonl CGTCCTGAGCAGAGGTGTTG 
ADAMTS8Fclon2 TGTACCAGCTGGACCAGCAG 1339 
ADAMTS8Rclon2 GAATCACAGGGGGCACAGCT 
Primers for HNT cDNA cloning 
…Tr^ 1 GCCACCATGIGATTACAAGGATGACGACGI 
Flag-HNTFclon ^ F X X G ^ G G G T C T G T G G G T A C C T G T T 1 0 7 3 b p 
HNTRclon ACTCACATCAAAATTTGAGAAGC 
Primers for BARX2 cDNA cloning 
Barx2Fclon CGCCGGCTCACCATGCACT 864bp 
Barx2Rclon AAGGGTTTTACTTTAGCTTAATGG 
Note: the sequence underlined indicates the Kozak the translation initiation sequence 
and the sequence boxed indicates the Flag tag sequence. 
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